Novel 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same

MYPI1998001259A0Inactive Publication Date: 1998-09-24IPSEN PHARMA SAS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI1998001259
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
1997-03-24
Filing Date
1998-03-24
Publication Date
1998-09-24
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current NO-synthase inhibitors and ROS traps have limitations in effectively treating various pathologies involving excessive NO and ROS production, such as cardiovascular disorders, neurodegenerative diseases, and cancer, with existing compounds showing incomplete efficacy and potential side effects.

Method used

Development of novel 2-(iminomethyl)amino-phenyl derivatives with inhibitory activity on NO-synthase enzymes and ROS trapping capabilities, represented by specific chemical formulas and their pharmaceutical compositions, which can be used as therapeutic agents for a wide range of diseases.

Benefits of technology

These derivatives demonstrate potential in treating multiple pathologies by effectively inhibiting NO-synthase and trapping ROS, offering a broader therapeutic spectrum and improved efficacy compared to existing compounds.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A SUBJECT OF THE INVENTION IS NEW DERIVATIVES OF 2-(IMINOMETHYL) AMINO-PHENYL, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
Need to check novelty before this filing date? Find Prior Art

Description

NOVEL 2-(IMINOMETHYL)AMINO-PHENYL DERIVATIVES,PREPARATION, APPLICATION AS MEDICINES ANDPHARMACEUTICAL COMPOSITIONS CONTAINING SAMEA subject of the present invention is new derivatives of 2-(iminomethyl)amino-phenyl which have an inhibitory activity on NO-synthase enzymes producingnitrogen monoxide NO and / or an activity which traps the reactive oxygen species(ROS). The invention relates to the derivatives corresponding to general formula (I)defined below, their preparation methods, the pharmaceutical preparationscontaining them and their use for therapeutic purposes, in particular their use as NO-synthase inhibitors and selective or non-selective traps for reactive oxygen species.Given the potential role of NO and the ROS's in physiopathology, the newderivatives described corresponding to general formula (I) may produce beneficialor favourable effects in the treatment of pathologies where these chemical speciesare involved. In particular:• cardio-vascular and cerebrovascular disorders including for example,atherosclerosis, migraine, arterial hypertension, septic shock, ischemic orhemorragic cardiac or cerebral infarctions, ischemias and thromboses.• disorders of the central or peripheral nervous system such as for exampleneurodegenerative diseases where there can in particular be mentioned cerebralinfarctions, sub-arachnoid haemorrhaging, ageing, senile dementias includingAlzheimer's disease, Huntington's chorea, Parkinson's disease, Creutzfeld Jacobdisease and prion diseases, amyotrophic lateral sclerosis, but also pain, cerebraland spinal cord traumas, addiction to opiates, alcohol and addictive substances,erective and reproductive disorders, cognitive disorders, encephalopathies,encephalopathies of viral or toxic origin.• disorders of the skeletal muscle and neuromuscular joints (myopathy, myosis) aswell as cutaneous diseases.proliferate and inflammatory diseases such as for example atherosclerosis,pulmonary hypertension, respiratory distress, glomerulonephritis, portalhypertension, psoriasis, arthrosis and rheumatoid arthritis, fibroses, amyloidoses,inflammations of the gastro-intestinal system (colitis, Crohn's disease) ordiseases affecting the pulmonary system and airways (asthma, sinusitis, rhinitis).• organ transplants.• auto-immune and viral diseases such as for example lupus, AIDS, parasitic andviral infections, diabetes, multiple sclerosis.• cancer.• neurological diseases associated with intoxications (Cadmium poisoning,inhalation of n-hexane, pesticides, herbicides), associated with treatments(radiotherapy) or disorders of genetic origin (Wilson's disease).• all the pathologies characterized by an excessive production or dysfunction ofNO and / or ROS'sIn all these pathologies, there is experimental evidence demonstrating theinvolvement of NO or ROS's {J. Med. Chem. (1995) 38, 4343-4362; Free Radio.Biol. Med. (1996) 20, 675-705; The Neuroscientist (1997) 3, 327-333).Moreover, NO Synthase inhibitors, their use and more recently the combination ofthese inhibitors with products possessing antioxidant or antiradicular properties havealready been described in earlier patents (patent US 5,081,148; patent US 5,360,925and an unpublished patent respectively). Patent Application WO-A-95 / 05363, whichis considered as being the closest prior art to the subject-matter of the presentinvention discloses derivatives of 2-(iminomethyl)amino-phenyl. The c6mpounds ofthis patent also have an inhibitory activity on NO synthase and they are used such <ismedicaments in particular in the treatment of neurodegenerative diseases ormigraine.A subject of the present invention is the derivatives of 2-(iminomethyl)amino-phenyl, their preparation and their use in therapeutics.The compounds of the invention correspond to the general formula (I):in which:A represents:either aradical in which Ri and R2 represent, independently, a hydrogen atom, a halogen, theOH group, a linear or branched alkyl or alkoxy radical with 1 to 6 carbon atoms,R3 represents a hydrogen atom, a linear or branched alkyl radical with 1 to 6 carbonatoms or a -COR4 radical,R4 representing a linear or branched" alkyl radical with 1 to 6 carbon atoms,or aradical in which R3 has the meaning indicated aboveradical in which R5 represents a hydrogen atom, the OH group or a linear orbranched alkyl or alkoxy radical with 1 to 6 carbon atoms;B represents a linear or branched alkyl radical with 1 to 6 carbon atoms, carbocyclicor heterocyclic aryl radical with 5 or 6 members containing 1 to 4 heteroatomschosen from O, S, N and in particular the thiophene, furane, pyrrole or thiazoleradicals, the aryl radical being optionally substituted by one or more groups chosenfrom the linear or branched alkyl, alkenyl or alkoxy radicals with 1 to 6 carbonatoms;X represents -Zr, -Zi-CO-, -CH=CH-CO-, -ZrNR3-CO-, -Z1-nr3-CS-,-Z1-nr3-SO2- or a single bond;Y represents a radical chosen from the -Z2-Q, piperazine, homopiperazine,2-methylpiperazine, 2,5-dimethylpiperazine, 4-aminopiperidine, -nr3-z2-Q-,-nr3-CO-z2-Q-, -nr3-NH-CO-z2-, -NH-NH-z2-, -nr3-O-z2-,-nr3-so2-nr3-z2-, -O-z2-Q-, -O-CO-z2-Q- or -S-z2-Q- radicals,in which Q represents a single bond, 0-Z3 , r3-N-z3 or S-Z3;Zj, Z2 and Z3 represent independently a single bond or a linear or branched alkyleneradical with 1 to 6 carbon atoms, Zu Z2 and Z3 preferably representing -(CH2)m-, mbeing an integer from 0 and 6;represents a hydrogen atom or an OH group;or are salts of the latter, with the exception however of the compound of thefollowing formula:The compounds of general formula (I) containing an asymmetrical centre presentisomer forms. The racemics and the enantiomers of these compounds also form partof this invention.The compounds of the invention can exist in the state of bases or addition salts inparticular with organic or inorganic acids or with bases, and in particular in the stateof hydrates, hydrochlorides, dihydrochlorides, fumarates or hemifumarates.By linear or branched alkyl having 1 to 6 carbon atoms, is meant in particular thesmethyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, pentyl,neopentyl, isopentyl, hexyl, isohexyl radicals. By linear or branched alkoxy having 1to 6 carbon atoms, is meant the radicals of which the radical alkyl has the meaningindicated previously.By halogen, is meant the fluorine, chlorine, bromine or iodine atoms.A'particular subject of the invention is the following compounds of general formula(I), described in the examples (for some in the form of a salt):- 3,5-bis-(l, 1 -dimethylethyl)-4-hydroxy-N-{4-[(2-thienyl(imino)methyl)amino]phenyl}-benzamide;- 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-{4-[[(2-thienyl(imino)methyl)amino]phenyl]methyl}-benzamide;-4-acetoxy-3,5-dimethoxy-N-{4-[[(2-thienyl(imino)methyl)amino]phenyl]methyl}-benzamide;- 3,5-dimethoxy-4-hydroxy-N- {4-[[(2-thienyl(imino)methyl)amino]phenyl]methyl} -benzamide;- 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{4-[2-[(2-thienyl-(imino)methyl)amino]phenyl]ethyl}-benzamide;- 4-acetoxy-3,5-dimethoxy-N- {4-[2-[(2-thienyl-(imino)methyl)-amino]phenyl]ethyl}-benzamide;- 3,5-dimethoxy-4-hydroxy-N-{4-[2-[(2-thienyl-(imino)methyl)-araino]phenyl]ethyl} -benzamide;- 3,4,5-trihydroxy-N-{4-[2-[(2-thienyl(imino)methyl)-amino]phenyl]ethyl}-benzamide;- N- {4-[4-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxybenzoyl]-1 -piperazinyl]-phenyl}-2-thiophenecarboximidamide;- N- {4-[4- [3,5 -bis-( 1,1 -dimethy lethyl)-4-hydroxybenzyl]-1 -piperazinyljphenyl} -2-thiophenecarboximidamide;- N- {4-[4-[3,5-dimethoxy-4-hydroxybenzoyl]-1 -piperazinyl]-phenyl} -2-thiophenecarboximidamide;- 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N- {4-[(2-thienyl(imino)methyl)amino]phenyl}-2H-l-benzopyran-2-carboxamide;- N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)-carbonyl]-1 -piperazinyljphenyl} -2-thiophenecarboximidamide;- N- {4-[4-[(5-methoxy- lH-indol-3-yl)methylcarbonyl]-1 -piperazinyljphenyl} -2-thiophenecarboximidamide;- N-[4-[4-[ {3-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl]-1 -oxo-2-propenyl} -1 -piperazinyl]-phenyl]]-2-thiophenecarboximidamide;- 3,5-bis-(l,l-dimethylethyl)-4-hydloxy-N-{3-[[(2-thienyl-(imino)methyl)amino]phenyl]methyl} -benzamide;- N-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl]-N'-{{4- [(2-thienyl(imino)methyl)amino]phenyl} methyl} -urea;- N-[5-[ {3-(3,5-bis-(l, 1 -dimethylethyl)-4-hydroxyphenyl)- l-oxo-2-propenyl}amino]-2-hydroxyphenyl]-2-thiophenecarboximidamide;- N-[3-[{3-(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl)-l-oxo-2-propenyl}-amino]-4-hydroxyphenyl]-2-thiophenecarboximidamide;- N- {4-[4-[3,4,5-trihydroxybenzoyl]-l-piperazinyl]phenyl}-2-thiophenecarboximidamide;-N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N' -{{4- [(2-thienyl(imino)methyl)amino]phenyl} carbonylamino} -urea;- N-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl] -N'- {{4- [(2 -thieny l(imino)methyl)amino]phenyl} methyl} -thiourea;- N-[3,5-bis-( 1,1 -dimethylethy l)-4-hydroxyphenyl] -N'-{2-{4-[(2-thienyl(imino)methyl)amino]phenyl}ethyl}-urea;- N-(4-{4- [(3,4-dihydro-6-methoxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonyl]-1 -piperazinyl} phenyl)-2-thiophenecarboximidamide;- N-[4- {4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H- l-benzopyran-2-yl)carbonyl]-1H-1,4-diazepin-1 -yl}phenyl]-2-thiophenecarboximidamide;- (R)-N- {4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-ben2:opyran-2-yl)-carbonyl] -1 -piperazinyljphenyl} -2-thiophenecarboximidamide;- (S)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)-carbonyl]-l-piperazinyl]phenyl}-2-thiophenecarboximidamide;- 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{2-[3-[(2-thienyl(imino)methyl)amino]phenyl]ethyl} -benzamide;- N- {4-(4-[2-(3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl)-1 -oxo-ethyl]-l-piperazinyl)phenyl}-2-thiophenecarboximidamide;- 2- {4-[(2-thienyl(imino)methyl)amino]phenyl}ethyl 3,5-bis-(l, 1 -dimethylethyl)-4-hydroxy-benzoate;- 2- {3-[(2-thienyl(imino)methyl)amino]phenyl}ethyl 3,5-bis-(l, 1 -dimethylethyl)-4-hydroxy-benzoate;- 2- {2-[(2-thienyl(imino)methyl)amino]phenyl} ethyl 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-benzoate;or one of the salts of one of the latter, in particular their hydrochlorides,dihydrochlorides, fumarates or hemi-fumarates.The compounds of general formula (I) are generally preferred in which:- X represents a linear or branched alkylene radical having 1 to 6 carbon atoms andY represents a piperazine, homopiperazine, 2-methylpiperazine,2,5-dimethylpiperazine, 4-aminopiperidine, -NR3-Z2-Q-, -nr3-NH-CO-z2 •,-NH-NH-z2- or -nr3-O-z2- radical;or-X represents -Zt-CO- or -CH=CH-CO- and Y represents a piperazine,homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, 4-aminopiperidine,-nr3-z2-Q-, -nr3-NH-CO-z2-, -NH-NH-z2-, -nr3-O-z2-, -O-z2-Q- or -nr3-CO-Q'- radical with Q' = r3-N-z3;or- X represents -ZrNR3-CO- and Y represents -Z2-Q-, -NH-Z2-Q-, -NH-CO-Z2-Q"-with Q" = O-z3-, r3-N-z3- or S-z3-, or Y represents -nr3-so2-nr3-z2- or-O-z2-Q-;or-X represents -Zj-NH-CO- and Y represents a piperazine, homopiperazine,2-methylpiperazine, 2,5-dimethylpiperazine, 4-aminopiperidine, -nr3-z2-Q-,-nr3-NH-CO-z2-, -NH-NH-z2- or -nr3-O-z2- radical;- X represents -Zi-NR3-S02- and Y represents -Z2-Q"- with Q" = O-z3-, r3-N-z3- orS-z3-, or Y represents -nr3-z2-Q-;or- X represents -Z\- and Y represents -O-CO-z2-Q-;or-X represents -Z1-nr3-CS- and Y represents -NH-z2-Q-, or a piperazins,homopiperazine, 2-methylpiperazine, 2,5-dimethyl-piperazine, 4-aminopiperidine,-nr3-z2-Q-, -NH-NH-z2- or -nr3-O-z2- radical;or- X represents a bond and Y represents -0-Z2-NH-, -S-Z2-NH-.Moreover the X-Y group will preferably be chosen from the following radicals:—z^c-n-zj-t—II Io r3in which T represents a single bond, the -NR3- radical or the -CO-nr3- radical,orin which Rp represents a hydrogen atom or a methyl radical,orin which U represents a -Z2, -nr3-CO-, -C0-Z2-0-, -CO-, -NR3- radical or anoxygen atom,ororthe Z\, Z2 and R3 radicals having the meaning indicated above.More preferentially, the compounds according to the invention are one of thefollowing compounds:- 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N- {4-[2-[2-thienyl-(iminomethyl)amino]phenyl]ethyl}-benzamide;- 3,4,5-trihydroxy-N-{4-[2-[2-thienyl(iminomethyl)-amino]phenyl]ethyl}-benzamide;- N- {4-[4-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxybenzoylj-1 -piperazinyljphenyl} -2-thiophenecarboximidamide;- N- {4-[4-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxybenzylJ-1 -piperazinyl]phenyl} -2-thiophenecarboximidamide;- 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-{4-[2- thienyl(iminomethyl)aminojphenyl} -2H-1 -benzopyran-2-carboxamide;- N- {4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1 -benzopyran-2-yl)-carbonyl]-1 -piperazinyl]phenyl} -2-thiophenecarboximidamide;- N- {4-[4-[(5 methoxy-1 H-indol-3-yl)methylcarbonyl]-1 -piperazinyljphenyl}-2-thiophenecarboximidamide;- 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N- {3-[[2-thienyl-(iminomethyl)amino]phenyl]methyl}-benzamide;- N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-{{4-[2-thienyl(iminomethyl)amino]phenyl}methyl}-urea;- N-[5-[{3-(3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl)-1 -oxo-2-propenyl}-amino]-2-hydroxyphenyl]-2-thiophenecarboximidamide;- N-[3-[{3-(3,5-bis-( 1,l-dimethylethyl)-4-hydroxyphenyl)-1 -oxo-2-propenyl}-amino]-4-hydroxyphenyl]-2-thiophenecarboximidamide;- N- {4-[4-[3,4,5-trihydroxybenzoylJ-1 -piperazinyljphenyl} -2-thiophenecarboximidamide;- N- [3,5 -bis-( 1,1 -dimethylethyl)-4-hydroxypheny 1] -N '-{{4-[2-tibdenyl(iminomethyl)amino]phenyl}carbonylamino}-urea;or a salt of one of the latter, in particular a hydrochloride, dihydrochloride, fumarateor hemi-fumarate of one of the latter.Other preferred compounds for the invention are the following compounds:- 4-acetoxy-3,5-dimethoxy-N- (4-[2-[(2-thienyl-(imino)methyl)-amino]phenyl]ethyl}-benzamide;- 3,5-dimethoxy-4-hydroxy-N-{4-[2-[(2-thienyl-(imino)methyl)-amino]phenyl]ethyl}-benzamide;or a salt of one of the latter, in particular a hydrochloride, dihydrochloride, fumarateor hemi-fumarate of one of the latter.Quite particularly preferred compounds for the invention are the following:- N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)-carbonyl]-1 -piperazinyljphenyl} -2-thiophenecarboximidamide;- (R)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)-carbonyl]-l-piperazinyl]phenyl}-2-thiophenecarboximidamide;- (S)-N-{4-[4-[(3,4-dihydro-6-hydrQxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)-carbonyl]-l-piperazinyl]phenyl}-2-thiophenecarboximidamide; ror a salt of one of the latter, in particular a hydrochloride, dihydrochloride, fumarateor hemi-fumarate of one of the latter.Finally, the compounds of general formula (I) presenting the following characteristicare particularly preferred for the invention:either:- A represents:- X represents -CO- or -NH-CO-;- and Y represents an -NH-z2-Q- or piperazine radical, Q representing a singlebond or an O-z3, r3-N-z3 or S-Z3 radical, and Z2 and Z3 representingindependently a bond or a linear or branched alkylene radical having 1 to 6carbon atoms and r3 represents a hydrogen atom or a linear or branched allcylradical having 1 to 6 carbon atoms.or: R^ is an OH group.A subject of the invention is also, as medicaments, the compounds of generalformula (I') described previously or their pharmaceutically acceptable salts. It alsorelates to pharmaceutical compositions containing these compounds or theirpharmaceutically acceptable salts, and the use of these compounds or of theirpharmaceutically acceptable salts in order to produce medicaments intended toinhibit neuronal NO synthase or inducible NO synthase, to inhibit lipidicperoxidation or to perform the double function of NO synthase inhibition and oflipidic peroxidation inhibition.By pharmaceutically acceptable salt, is meant in particular addition salts withinorganic acids such as hydrochloride, sulphate, phosphate, diphosphate,hydrobromide and nitrate or with organic acids such as acetate, maleate, fumarate,tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate,pamoate, oxalate and stearate. Also included within the scope of the presentinvention, when they can be used, are the salts formed from bases su6h as that ofsodium or potassium hydroxide. For other examples of pharmaceutically acceptablesalts, reference can be made to "Pharmaceutical salts", J. Pharm. Sci. 66:1 (1977).The pharmaceutical composition can be in the form of a solid, for example powders,granules, tablets, gelatin capsules, liposomes or suppositories. Appropriate solidsupports can be, for example, calcium phosphate, magnesium stearate, talc, sugai-s,lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethylcellulose, polyvinylpyrrolidine and wax.The pharmaceutical compositions containing a compound of the invention can alsobe presented in liquid form, for example, solutions, emulsions, suspensions orsyrups. Appropriate liquid supports can be, for example, water, organic solventssuch as glycerol or the glycols, similarly their mixtures, in varying proportions, inwater.The administration of a medicament according to the invention can be carried out bytopical, oral, parenteral route, by intramuscular injection, etc.The administration dose envisaged for a medicament according to the invention iscomprised between 0.1 mg and 10 g depending on the type of active compound used.The invention also offers, as new industrial products, the synthesis intermediates ofthe products of general formula (I), namely the products of general formula (II)A:in which:W represents a amino or nitro radical,A represents:either aradical, in which Ri and R2 represent, independently, a hydrogen atom, a halogen,the OH group, a linear or branched alkyl or alkoxy radical having 1 to 6 carbonatoms,R3 represents a hydrogen atom, a linear or branched alkyl radical having 1 to 6carbon atoms or a -COR4 radical,R4 representing a linear or branched alkyl radical having 1 to 6 carbon atoms,or aradical, in which R3 has the meaning indicated aboveradical, in which R5 represents a hydrogen atom, the OH group or a linear orbranched alkyl or alkoxy radical having 1 to 6 carbon atoms;X represents -Zr, -Zi-CO-, -CHCH-CO-, -Z1-nr3-CO-, -Z1-nr3-CS-,-Z1-nr3-SO2- or a single bond;Y represents a radical chosen from the -z2-Q, piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, 4-aminopiperidine, -nr3-z2-Q-,-nr3-CO-z2-Q-, -nr3-NH-CO-z2-, -NH-NH-z2-, -nr3-O-z2-,-nr3-so2-nr3-z2-, -O-z2-Q-, -O-CO-z2-Q- or -S-z2-Q- radicals,in which Q represents a single bond, O-z3 , r3-N-z3 or S-z3;Z[, Z2 and z3 represent independently a single bond or a linear or branched alkyleneradical having 1 to 6 carbon atoms; preferably, Zi, Z2 and z3 represent -(CH2)m-, inbeing an integer comprised between 0 and 6;^represents a hydrogen atom or an OH group;rwith the exception however of 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-nitrophenyl)-benzamide;or the salts of the latter, with the exception however of compounds corresponding tothe following formulae:Moreover, the invention offers in particular, as new industrial products, thefollowing compounds, which are intermediates in the synthesis of the products ofgeneral formula (I):- 3,5 -bis-( 1,1 -dimethylethyl)-4-hydroxy-N-(4-aminopheny l)-benzamide;- 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-[(4-nitrophenyl)methyl]-benzamide;- 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-[(4-arninophenyl)methyl]-benzamide;- 4-acetoxy-3,5-dimethoxy-N-[(4-nitrophenyl)methyl]-benzamide;- 4-acetoxy-3,5-dimethoxy-N-[(4-aminophenyl)methyl]-benzamide;- 3,5-bis-(l, 1 -dimethylethyl)-4-hydroxy-N-[2-(4-nitrophenyl)ethyl]-benzamide;- 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-[2-(4-aminophenyl)ethyl]-benzamide;- 4-acetoxy-3,5-dimethoxy-N-[2-(4-nitrophenyl)ethyl]-benzamide;- 4-acetoxy-3,5-dimethoxy-N-[2-(4-aminophenyl)ethyl]-benzamide;- 3,4,5-trihydroxy-N-[2-(4-nitrophenyl)ethyl]-benzamide;- 3,4,5-trihydroxy-N-[2-(4-aminophenyl)ethyl]-benzamide;- 2,6-bis-( 1,1 -dimethylethyl)-4- {[4-(4-nitrophenyl)-1 -piperazinyl]-carbonyl} -phenol;- 2,6-bis-( 1,1 -dimethylethyl)-4- {[4-(4-aminophenyl)-1 -piperazinylj-carbonyl} -phenol;- 2,6-bis-( 1,1 -dimethylethyl)-4- {[4-(4-nitrophenyl)-1 -piperazinyl]-methyl} -phenol;- 2,6-bis-( 1,1 -dimethylethyl)-4- {[4-(4-aminophenyl)- l-piperazinyl]-methyl} -phenol; .- 2,6-dimethoxy-4- {[4-(4-nitrophenyl)-1 -piperazinyl]carbonyl} -phenol;- 2,6-dimethoxy-4- {[4-(4-aminophenyl)-1 -piperazinyl]carbonyl} -phenol;- 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(4-nitrophenyl)-2H-l-benzopyran-2-carboxamide;- 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(4-aminophenyl)-2H-l-benzopyran-2-carboxamide;- 3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-nitrophenyl)-l-piperazinyl]-carbonyl}-2H-1 -benzopyran-6-ol;- 3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-aminophenyl)-l-piperazinyl]-carbonyl} -2H-1 -benzopyran-6-ol;- 1 -[(5 methoxy-1 H-indol-3-yl)methylcarbonyl]-4-(4-nitrophenyl)-piperazine;- l-[(5 methoxy-lH-indol-3-yl)methylcarbonyl]-4-(4-aminophenyl)-piperazine;- 2,6-bis-(l,l-dimethylethyl)-4-{3-[4-(4-nitrophenyl)-l-piperazinyl]-3-oxo-2-propenyl}-phenol;- 2,6-bis-( 1,1 -dimethylethyl)-4- (3-[4-(4-aminophenyl)-1 -piperazinyl]-3-oxo-2-propenyl}-phenol;- 3,5-bis-(lJ-dimethylethyl)-4-hydroxy-N-[(3-nitrophenyl)methyl]-benzamide;- 3,5-bis-(l, 1 -dimethylethyl)-4-hydroxy-N-[(3-armnopheayl)methyl]-beiizainide;- N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-[(4-nitrophenyl)methyl]-urea;- N-[(4-aminophenyl)methyl]-N'-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl] -urea;- 3-[(3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl]-N-(4-hydroxy-3-nitrophenyl)-2-propenamide;- 3-[(3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl]-N-(4-hydroxy-3-aminophenyl)-2-propenamide;- 3-[(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N-(2-hydroxy-5-nitrophenyr)-2-propenamide;- 3-[(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N-(2-hydroxy-5-aminophenyl)-2-propenamide;- 5-{[4-(4-nitrophenyl)-l-piperazinyl]carbonyl}-benzene-l,2,3-triol;- 5- {[4-(4-aminophenyl)-1 -piperazinyl] carbonyl} -benzene-1,2,3 -triol;- N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-[(4-nitrophenyl)-carbonylamino]-urea;- N-[(4-aminophenyl)carbonylamino]-N'-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenylj-urea;- N-[3,5-bis-(l, l-dimethylethyl)-4-hydroxyphenyl]-N'-[(4-nitrophenyl)methyl]-thiourea;- N-[(4-aminophenyl)methyl]-N' -[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl]-thiourea;4- N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-[2-(4-nitrophenyl)ethyl]-urea;- N-[2-(4-aminophenyl)ethyl]-N'-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-urea;1 - {[3,4-dihydro-6-raethoxy-2,5,7,8-tetramethyl-2H-1 -benzopyran-2-y 1] carbonyl} -4-(4-nitrophenyl)piperazine;l-{[3,4-dihydro-6-methoxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl]carbonyl} -4-(4-aminophenyl)piperazine;- hexahydro-4-(4-nitrophenyl)-lH-l,4-diazepine;l-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonyl]hexahydro-4-(4-nitropheny 1)-1H-1,4-diazepine;l-(4-aminophenyl)-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonyl] hexahydro-1H-1,4-diazepine;- N-[4-{4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonyl]-1H-1,4-diazepin-1 -yl} phenyl]-2-thiophenecarboximidamidehydrochloride;- (fl)-3,4-dihydro-2,5,7,8-tetramethyl-2- {4-[(4-nitrophenyl)-1 -piperazinyl]-carbonyl} -2H-1 -benzopyran-6-ol;- (i?)-3,4-dihydro-2,5J,8-tetramethyl-2-{4-[(4-aminophenyl)-l-piperazinyl]-carbonyl}-2H-1-benzopyran-6-ol;- (S)-3,4-dihydro-2,5,7,8-tetramethyl-2- {4-[(4-nitrophenyl)-1 -piperazinyl]-carbonyl} -2H-1 -benzopyran-6-ol;- (S)-3,4-dihydro-2,5,7,8-tetramethyl-2- {4-[(4-aminophenyl)-1 -piperazinyl]-carbonyl} -2H-1 -benzopyran-6-ol;- 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[2-(3-nitrophenyl)ethyl]-benzamide;- 3,5-bis-(lJ-dimethylethyl)-4-hydroxy-N-[2-(3-aininophenyl)ethyl]-benzaraide;- 2-(4-nitrophenyl)ethyl 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxybenzoate;- 2-(4-aminophenyl)ethyl 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-benzoateor their salts.Finally, the invention offers preparation processes for the compounds of generalformula (I) as defined above and consisting, for example, of the reaction in a loweralcohol, such as methanol, ethanol, isopropyl alcohol or t-butanol, preferably inisopropyl alcohol, at a temperature'comprised between 20 and 90 °C, for example at50 °C, and for one to 48 hours, preferably for 15 to 24 hours, optionally in thepresence of DMF, of a compound of general formula (III) as defined above with acompound general formula (IV)said compound of general formula (IV) being optionally salified by a mineral acidG, B having the meaning indicated above and L representing a leaving group and inparticular an aikoxy, thioalkyl, sulphonic acid, halide, aryl alcohol or tosyl radical(other leaving groups well known to a person skilled in the art and being able to beoptionally used for the invention are described in the following work: AdvancedOrganic Chemistry, J. March, 3rd Edition (1985), Mc Graw-Hill, p. 315).Preferably, G represents HC1, HBr or HI.Other manufacturing processes can be envisaged and are accessible in the literature(for example: The Chemistry of amidines and imidates, Vol. 2, Saul PATAI and ZviRAPPOPORT, John Wiley & Sons, 1991).In accordance with the invention, the compounds of general formula (I) can beprepared by the process described hereafter.Preparation of the compounds of general formula (I):The compounds of general formula (I) can be prepared from the intermediates ofgeneral formula (II) according to Diagram 1.Reduction of the nitro function of the intermediates of general formula (II) isgenerally carried out by catalytic hydrogenation, in ethanol, in the presence of Pd / C,except in the case where X = -CH=CH-CO- or Y = -0-CH2-, the nitro group isselectively reduced using, for example, SnCl2 (J. Heterocyclic Chem. (1987), 24,927-930; Tetrahedron Letters (1984), 25, (8), 839-842). The reaction is then carriedout while heating the mixture at about 70° C, for at least three hours, in ethyl acetatesometimes with added ethanol.The aniline derivatives of general formula (III), thus obtained, can be condensedwith the derivatives of general formula (IV), for example the derivatives of O-all^lthioimidate or S-alkyl thioimidate Type, in order to produce the final compounds ofgeneral formula (I) (cf. Diagram 1). For example, for B = thiophene, the derivativesof general formula (III) can be condensed with S-methylthiophene thiocarboxamidehydroiodide, prepared according to a method in the literature (Ann. Chim. (1962), 7,303-337). The condensation can be carried out by heating in an alcohol (forexample in methanol or isopropanol), optionally in the presence of DMF at atemperature preferably comprised between 50 and 100 °C for a duration general lycomprised between a few hours and overnight.Preparation of the intermediates of general formula (II):The intermediates of general formula (II) can be prepared by different processesaccording to the chemical functions which are used: amines, carboxamides, ureas,thioureas, sulphonamides, aminosulphonylureas, sulphamides, carbamates, ethers,esters, thioethers, acylureas, etc.:When: X = linear or branched alkylene radical having 1 to 6 carbon atomsand Y = piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethyl-piperazine, 4-aminopiperidine, -NR3-z2-Q-, -nr3-NH-CO-z2-,-NH-NH-z2-, -nr3-O-z2-The amines of general formula (II), Diagram 2, in which A, X, Y and are asdefined above, can be obtained by nucleophilic substitution of the halogenatedderivatives of general formula (VI) by an amine of general formula (VII). Thereaction is carried out, for example, in DMF in the presence of K2CO3 at 20° C. Thehalogenated derivatives of general formula (VI) are accessible, for example, bybromination of the primary alcohols of general formula (V) using PBr3, at 0°C, inanhydrous THF. The alcohols of general formula (V) which are not commerciallyavailable can be prepared according to methods described in the literature(:Tetrahedron Lett. (1983), 24, (24), 2495-2496).Diagram 2:The amines of general formula (VII) in which Y represents homopiperazine,2,5-dimethylpiperazine, 4-aminopiperidine or more generally -nr3-z2-nr3-, aresynthesized in three stages starting from the corresponding commercial diamines.The diamines are selectively mono-protected in the form of carbamate (Synthesis(1984), (12), 1032-1033; Synth. Commun. (1990), 20, (16), 2559-2564) beforereacting by nucleophilic substitution on a fluoronitrobenzene, in particular 4-fluoronitrobenzene. The amines, which were previously protected, are released atthe last stage, according to methods described in the literature (T.W. Greene andrP.G.M. Wuts, Protective Groups in Organic Synthesis, Second edition (Wilev-Interscience, 1991)), in order to produce the intermediates of general formula (VII).When:The carboxamides of general formula (II), Diagram 3, in which A, X, Y and R6 areas defined above, are prepared by condensation of the commercial carboxylic acidsof general formula (VIII) for X = -Zj-CO- and general formula (IX) for X ==-CH=CH-CO- with the amines of general formula (VII). The non-commercial acidscan be synthesized according to methods similar to those described in the literature{J. Org. Chem. (1974), 39 (2), 219-222; J. Amer. Chem. Soc. (1957), 79, 5019-5023,and CHIMA (1991), 45 (4), 121-123 when A represents a 6-alkoxy-2,5,7,8-tetramethylchromane radical). The amines of general formula (VII) in which Yrepresents homopiperazine, 2,5-dimethylpiperazine, 4-aminopiperidine, or moregenerally -nr3-z2-NR3- are prepared according to methods analogous to thosedescribed in the preceding paragraph. The carboxamides bonds are formed understandard conditions for peptide synthesis (M. Bodanszky and A. Bodanszky, ThePractice of Peptide Synthesis, 145 (Springer-Verlag, 1984)) in THf,dichloromethane or DMF in the presence of a coupling reagent such asdicyclohexylcarbodiimide (DCC), l.l'-carbonyldiimidazole (CDI) (J. Med. Chem.(1992), 35 (23), 4464-4472) or l-(3-dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride (EDC or WSCI) (John Jones, The chemical synthesis of peptides, 54(Clarendon Press, Oxford, 1991)).Diagram 3:The carboxamides of general formula (II) in which A, X, Y and Rg are as definedabove, can also be prepared, Diagram 4, by peptide condensation of to amine ofgeneral formula (X) with a commercial acid of general formula (XI). When X =-nr3-CO- and R3 = H, the compounds of general formula (X) are anilines which areobtained by hydrogenation, in the presence of a catalytic quantity of Pd / C, ofcorresponding nitrobenzene derivatives, themselves synthesized according to amethod described in the literature (J. Org. Chem. (1968), 33 (1), 223-226). When Xt -NR3-CO- and r3 is a linear or branched alkyl radical having 1 to 6 carbon atoms,the monoalkylamines can be obtained according to a process described in theliterature (patents U.S. 3.208.859 and U.S. 2.962.531). The non-commercialcarboxylic acids of general formula (XI), are accessible from methods described inthe literature (Acta Chem. Scand. (1983), 37, 911-916; Synth. Commun. (1986), 16(4), 479-483; Phophorus, Sulfur Silicon Relat. Elem. (1991), 62, 269-273).The ureas of general formula (II), Diagram 5, in which A, X, Y and R6 are asdefined above, are prepared by adding an amine of general formula (X) to anisocyanate of general formula (XII), (XIII) or (XIV) in a solvent such as chlorofonnat 20°C. The synthesis of the non-commercial isocyanates of general formula (XM)is described in the literature {J. Med. Chem. (1992), 35 (21), 3745-3754). Theintermediate halogenated ureas (XV) and (XVII) are then substituted by a derivativeof general formula (XVI), in which Q represents O-z3-, r3-N-z3- or S-z3-, in thepresence of a base such as, for example, k2co3 or NaH in an aprotic solvent such asTHF or DMF in order to finally produce to the ureas of general formula (II).When:When: X = -Zj-NH-CO-«and Y = piperazine, homopiperazine, 2-methylpiperazine,2,5-dimethylpiperazine, 4-aminopiperidine, -nr3-z2-Q-,-NR3-NH-CO-Z2-, -NH-NH-z2-, -nr3-O-z2-The ureas of general formula (II), Diagram 6, in which A, X, Y and R^ are ;isdefined above, are prepared by the addition of an amine of formula general (VII),described previously, to an isocyanate of formula general (XVIII) in the presence ofa base such as diisopropylethylamine.The isocyanates of general formula (XVIII) are synthesized from the primaryamines of general formula (X), described previously, triphosgene and a tertiaryamine (J. Org. Chem. (1994), 59 (7), 1937-1938).The amines of general formula (VII) in which Y ± -NH-O- are prepared according toa method described in the literature (J. Org. Chem. (1984), 49 (8), 1348-1352).When:The aminosulphonylureas of general formula (II), Diagram 7, in which A, X, Y and^ are as defined above, are prepared by adding the amines of general formula (X),described previously, to chlorosulphonylisocyanate (J. Med. Chem. (1996), 39 (6),1243-1252). The intermediate chlorosulphonylurea (XIX) is then condensed withthe amines of general formula (VII), described previously, in order to produce theaminosulphonylureas of general formula (II) which can be optionally alkylated by ahalogenated derivative in the presence of a base such as, for example, NaH in orderto produce the derivatives of general formula (II).The sulphonamides of general formula (II), Diagram 8, in which A, X, Y and R6 areas defined above, are prepared by adding the amines of general formula (X),described previously, to the halogenoalkylsulphonyl chlorides of general formula(XX). The halogenoalkylsulphonamides of general formula (XXI), obtainedintermediately, are then condensed with an alcohol, an amine or a thiol of generalformula (XVI) in the presence of a base such as, for example, K2C03 or NaH, in apolar solvent such as, for example, acetonitrile or DMF.Diagram 8:When:The sulphamides of general formula (II), Diagram 9, in which A, X, Y and R^ are asdefined above are prepared in three stages starting from the amines of general*formula (X) and chlorosulphonylisocyanate. The reaction of an alcohol, such astBuOH, on the isocyanate function of chlorosulphonylisocyanate (Tetrahedron Lett(1991), 32 (45), 6545-6546) leads to an intermediate of chlorosulphonylcarbamatetype, which reacts in the presence of an amine of general formula (X) in order toproduce a derivative of carboxylsulphamide type of general formula (XXII).Treatment of this intermediate in a strong acid medium allows the sulphamidederivative of general formula (XXIII) to be obtained. Alkylation of the compoundsof general formula (XXIII) by the halogenated derivatives of general formula(XXIV) in the presence of a base such as, for example, NaH in a polar aproticsolvent allows the sulphamide derivatives of general formula (II) to be obtained.When:The carbamates of general formula (II), Diagram 10, in which A, X, Y and are astdefined above, are prepared by reaction of the amines of general formula (X),described previously, with the chloroformate derivatives of general formula (XXV)prepared according to a method described in the literature (Tetrahedron Lett. (1993),34 (44), 7129-7132).Diagram 10:The esters of general formula (II), Diagram 11, in which A, X, Y and R^ are asdefined above, are prepared by reaction of the acids of general formula (VIII) or(IX) and the alcohols of general formula (XXVI) in the presence ofdicyclohexylcarbodiimide and a catalytic quantity of 4-dimethylaminopyridine in asolvent such as, for example, THF or DMF at 20° C.Diagram 11:When:The esters of general formula (II), Diagram 12, in which A, X, Y and are asdefined above, can also be prepared by reaction of the acids of general formula (XJ[),described previously, with the alcohols of general formula (V) under the conditions*described previously.Diagram 12:When: X = -Z!-NR3-CS-and Y = -NH-z2-Q-, piperazine, homopiperazine, 2-methylpiperazine,2,5-dimethylpiperazine, 4-aminopiperidine, -nr3-z2-Q-,-NH-NH-z2-, -nr3-O-z2-The thioureas of general fonnula (II) in which A, X, Y and R^ are as defined above,are prepared from the ureas described previously using Lawesson's reagent,following an experimental protocol described in the literature (J. Med. Chem.(1995), 38 (18), 3558-3565).When:The etheroxides or thioetheroxides of general formula (II), Diagram 13, in which A,X, Y and R^ are as defined above are prepared from the dihydroquinones of generalformula (XXVII) (J. Chem. Soc., Perkin Trans. I, (1981), 303-306) or thethiophenols of general formula (XXVIII) (Bio. Med. Chem. Letters, (1993), 3 (12),2827-2830) and an electrophile (E4) such as, for example, bromoacetonitrile or 4-nitrophenyloxazolinone, in the presence of K2CO3 (J. Heterocyclic Chem., (1994),31, 1439-1443). The nitriles must be reduced (lithium hydride or catalytichydrogenation) in order to produce the intermediates of general formula (XXIX) or(XXX). Opening of the nitrophenyloxazolinones, accessible by reaction of thecorresponding nitroanilines with chloroethylchloroformiate as described in theliterature (J. Am. Chem. Soc.,(1953), 75, 4596), by phenols or thiophenols leadsdirectly to the compounds of general fonnula (XXIX) or (XXX) which are thencondensed with fluoronitrobenzene in order to produce the intermediates of generalformula (II).Diagram 13:The acylureas of general formula (II), Diagram 14, in which A, X, Y and are asdefined above are prepared by condensation of the acids of general formula (VIII) or(IX), Diagram 3, and the ureas of general formula (XXXI) in the presence of acoupling agent in a standard fashion used in peptide synthesis, as describedpreviously, in a solvent such as, for example, dichloromethane or DMF. The ureasof general formula (I) are accessible from the isocyanates of general formula (XII),Diagram 5, according to a method in the literature (J. Chem . Soc., Perkin Trans. 1,(1985), (1), 75-79).Diagram 14:•Unless defined in another manner, all the technical and scientific terms used herehave the same meaning as that usually understood by an ordinary specialist in thefield to which this invention belongs. Similarly, all the publications, patentapplications, all the patents and all other references mentioned here are incorporatedby way of reference.The following examples are presented in order to illustrate the above procedures andshould in no event be considered as limiting the scope of the invention.Example 1: 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{4-[(2-thienyl(imino)methyl)amino]phenyl}-benzamide hydrochloride: 11.1) 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-nitrophenyl)-benzamide:1.38 g (10 mmoles) of 4-nitroaniline, 2.5 g (10 mmoles) of 3,5-di-ter / -butyl-4-hydroxybenzoic acid and 2.26 g (11 mmoles) of dicyclohexylcarbodiimide areintroduced into a 250 ml flask containing 20 ml of THF. The reaction mixture isstirred for 15 hours at ambient temperature, the precipitate which appears is filteredand rinsed with ethyl acetate. After concentration of the solution under reducedpressure, the residue is diluted in 20 ml of ethyl acetate and the insoluble part isfiltered. The solvent is eliminated under vacuum and the residue is precipitated fromdiethyl ether. The solid is recovered by filtration, rinsed abundantly with diethylether in order to obtain a white powder with a yield of 65 %. Melting point: 277-278 °C.NMR 'H (100 MHz, DMSO d6, 5): 10.72 (s, 1H, CONH); 8.30 (m, 4H, Ph-N02);7.80 (s, 2H, Ph); 1.60 (s, 18H, 2x tBu).1.2) 3,5-bis-(l,l-dimethylethyI)-4-hydroxy-N-(4-aminophenyl)-benzamide:2.4 g (6.5 mmoles) of 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-nitrophenyl)-benzamide is dissolved in 50 ml of a mixture of absolute ethanol / dichloromethane^1 / 1) in a 250 ml Parr flask in the presence of 10 % Pd / C. The mixture is stirredunder 20 PSI of hydrogen, at 30 °C, for one hour. After filtration on celite, thefiltrate is concentrated under vacuum. The evaporation residue is taken up in 25 :mlof a 1M solution of HC1. The precipitate formed is filtered and rinsed with 50 ml ofdiethyl ether followed by 50 ml of ethyl acetate. The amine is released from its saltby stirring in a mixture of 50 ml of ethyl acetate and 50 ml of 1M NaOH. Afterdecantation, the organic phase is washed with 25 ml of 1M NaOH and 25 ml of saltwater. The organic solution is dried over sodium sulphate, filtered, rinsed andconcentrated to dryness under reduced pressure in order to produce 1.09 g (49 %) ofa white powder. Melting point: 220-221 °C.NMR 'H (100 MHz, DMSO d6, 5): 9.80 (s, 1H, CONH); 7.78 (s, 2H, Ph); 7.05 (m,4H, Ph-NH2); 5.02 (s, 2H, OH); 1.60 (s, 18H, 2x tBu).1.3) 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{4-[(2-thienyl (imino)methyl)-amino]phenyl}-benzaraide hydrochloride: 1880 mg (3.08 mmoles) of S-methyl-2-thiophenethiocarboximide hydroiodide (Ann.Chim. (1962), 7, 303-337) is added to a 100 ml flask containing a solution of 1.05 g(3.08 mmoles) of 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide in 20 ml of 2-propanol. After heating at 50° C for 15 hours, the reactionmixture is concentrated to dryness under vacuum. The residue is taken up in 50 mlof ethyl acetate and 50 ml of a saturated solution of sodium carbonate. Afterdecantation, the organic phase is washed successively with 50 ml of a saturatedsolution of sodium carbonate, 50 ml of water and 50 ml of salt water. The organicsolution is dried over sodium sulphate, filtered and evaporated under reducedpressure. The crystals obtained are taken up in diethyl ether, filtered and washedsuccessively with ethyl acetate and acetone. 0.77 g of base is obtained with a yieldof 58%.The hydrochloride is prepared from 0.77 g (1.71 mmole) of base dissolved in 60 mlof methanol and salified in the presence of 3.42 ml (3.42 mmoles) of a molarsolution of HC1 in anhydrous diethyl ether. After stirring for 30 minutes at ambienttemperature, the solvent is evaporated off under vacuum and the residue isprecipitated in the presence of diethyl ether. The crystals obtained are filtered andrinsed abundantly with diethyl ether in order to finally obtain after drying 0.65 g(43 %) of a pale yellow powder. Melting point: 290-291 °C.NfylR *H (400 MHz, DMSO d6, 5): 11.55 (s, 1H, NH+); 10.40 (s, 1H, CONH);9.83 (s, 1H, NH+); 8.85 (s, 1H, NH4); 8.21 (m, 2H, thiophene);7.70 (s, 2H, Ph); 7.67 (m, 4H, Ph-NH); 7.60 (s, 1H, OH);7.40 (m, 1H, thiophene); 1.42 (s, 18H, 2x tBu).IR: v0H: 3624 cm"1, 3430 cm'1; Vc=o (amide): 1653 cm"1;Vc=n (amidine): 1587 cm"1.Example 2: 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{4-[[(2-thienyl-(imino)methyl)amino]phenyl]methyl}-benzamide hydrochloride: 22.1) 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[(4-nitrophenyl)methyl]-benzamide:1.88 g (10 mmoles) of p-nitrobenzylamine hydrochloride, 2.5 g (10 mmoles) of 3,5-di-tert-butyl-4-hydroxybenzoic acid, 1.38 ml (10 mmoles) of triethylamine and 2.26g (11 mmoles) of dicyclohexylcarbodiimide are introduced into a 250 ml flaskcontaining 25 ml of THF. The reaction mixture is stirred for 15 hours at ambienttemperature, the precipitate which appears is filtered and rinsed with a minimumamount of ethyl acetate. After concentration of the solution under reduced pressure,the residue is precipitated from a mixture of ethyl acetate / diethyl ether (1 / 4) andfiltered. The crystals are washed abundantly with diethyl ether in order to finallyobtain, after drying, a white powder with a yield of 74 % (2.85 g). Meltingpoint: 230-231 °C.NMR (100 MHz, cdci3, 5): 7.85 (m, 4H, Ph-N02); 7.69 (s, 2H, Ph);6.82 (m, 1H, NHCO); 5.67 (s, 1H, OH); 4.75 (d, 2H, CH,-NHCO. J = 6.5 Hz); 1.49(s, 18H, 2x tBu).2.2) 3,5-bis-(l,l-dimethyIethyl)-4-hydroxy-N-[(4-aminophenyl)methyI]-benzamide:2.85 g (7.4 mmoles) of 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[(4-nitrophenyl)methyl]-benzamide are dissolved in 30 ml of a mixture of absoluteethanol / dichloromethane (1 / 1) in a 250 ml Parr flask, in the presence of 10 % Pd / C.The mixture is stirred under 20 PSI of hydrogen, at 30° C, for one hour. Afterfiltration on celite, the filtrate is concentrated under vacuum. The evaporationresidue crystallizes spontaneously. After leaving at rest overnight, the crystals arefiltered and rinsed with a mixture of diethyl ether (45 ml) and acetone (5 ml). 1.63 g(62 %) of a white powder is obtained. Melting point: 188-189° C.NMR lH (100 MHz, CDC13, 8): 7.62 (s, 2H, Ph); 6.95 (m, 4H, Ph-NH2);6.20 (m, 1H, NHCO); 5.58 (s, 1H, OH); 4.50 (d, 2H, CH2-NHCO, J = 6.5 Hz); 3.70(broad s, 2H, NH2); 1.47 (s, 18H, 2x tBu).2.3) 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{4-[[(2-thienyl-(imino)methyl)-amino]phenyl]methyI}-benzamide hydrochloride: 2The experimental protocol used is the same as that described for compound 1,with 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-[(4-aminophenyl)methyl]-benzamidereplacing 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide.After salification with a molar solution of HC1 in anhydrous diethyl ether, a whitepowder is obtained with a yield of 56 %. Melting point: 218-219 °C.NMR 'H (400 MHz, DMSO d6, 5): 11.60 (s, 1H, NH+); 9.83 (s, 1H, NH+); 9.02 (s,1H, CONH); 8.90 (s, 1H, NH+); 8.18 (m, 2H, thiophene); 7.70 (s, 2H, Ph); 7.42 (m,6H, thiophene, Ph-NH, OH); 4.50 (d, 2H, CH7-NHCO. J = 5.7 Hz); 1.40 (s, 18H, 2xtBu).IR: v0H: 3624 cm"1, 3424 cm"1; vc=0 (amide): 1644 cm"1;Vc=n (amidine): 1568 cm"1.Example 3: 4-acetoxy-3,5-dimethoxy-N-{4-[[(2-thienyl(imino)methyl)amino]phenyl]methyl}-benzamide: 33.1) 4-acetoxy-3,5-dimethoxy-benzoic acid:1.50 g (7.57 mmoles) of syringic acid is dissolved in 15 ml of dry pyridine in a 100ml flask, under a nitrogen atmosphere. 0.86 ml (9.08 mmoles) of acetic anhydride isadded dropwise and the mixture is stirred at ambient temperature for 18 hours. Thepyridine is evaporated off under reduced pressure, the residue is taken up in 25 ml ofdichloromethane and washed with 10 ml of a molar solution of HC1 then with2 x 10 ml of water. The organic phase is dried over sodium sulphate, filtered andevaporated under vacuum. 1.72 g (95 %) of a beige powder is obtained. Meltingpoint: 181-183 °C.NMR lH (100 MHz, cdci3, 8): 8.15 (s, 1H, C02H); 7.40 (s, 2H, Ph);3.90 (s, 6H, 2x och3); 2.40 (s, 3H, CH3).3.2) 4-acetoxy-3,5-dimethoxy-N-[(4-nitrophenyl)methyl]-benzamide:The experimental protocol used is the same as that described for intermediate 2.1,with 4-acetoxy-3,5-dimethoxy-benzoic acid replacing 3,5-di-te / 7-butyl-4-hydroxy-benzoic acid. A colourless oil is obfained with a yield of 28 %.NMR (100 MHz, DMSO d6, 5): 9.26 (t, 1H, NHCO, J = 6.0 Hz);7.91 (m, 4H, Ph-N02); 7.31 (s, 2H, Ph); 4.65 (d, 2H, CH2, J = 6.0 Hz);3.,83 (s, 6H, 2x OCH3); 2.28 (s, 3H, CH3).3.3) 4-acetoxy-3,5-dimethoxy-N-[(4-aminophenyl)methyl]-benzamide:The experimental protocol used is the same as that described for intermediate 2.2,with 4-acetoxy-3,5-dimethoxy-N-[(4-nitrophenyl)methyl]-benzamide replacing 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-[(4-nitrophenyl)methyl]-benzamide. Acolourless oil is obtained with a yield of 82 %. The product is used directly in thefollowing stage without additional purification.3.4) 4-acetoxy-3,5-dimethoxy-N-{4-[[(2-thienyl(imino)methyI)amino]phenyI]methyI}-benzamide: 3The experimental protocol used is the same as that described for compound 1, with4-acetoxy-3,5-dimethoxy-N-[(4-aminophenyl)methyl]-benzamide replacing 3,5-biis-(l,l-dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide. The base 3 isobtained in the form of a beige powder with a yield of 65 %. Meltingpoint: 47-48 °C.NMR [H (400 MHz, DMSO d6, 5): 9.08 (broad s, 1H, CONH); 7.75 (m, 1H,thiophene); 7.62 (m, 1H, thiophene); 7.30 (s, 2H, Ph); 7.10 (m, 1H, thiophene); 7.07(m, 4H, Ph-N); 6.48 (broad s, 2H, NH2); 4.50 (d, 2H, CH2, J = 4.6 Hz); 3.80 (s, 6H,2x OCH3); 2.30 (s, 3H, CH3).IR: Vc=o (ester): 1760 cm"1' Vc=o (amide): 1630 cm"1' Vc=n (amidine): 1540 cm"1.Example 4: 3,5-dimethoxy-4-hydroxy-N-{4-[[(2-thienyl(imino)methyl)amino]phenyl] methyl}-benzamide: 41 ml (2 mmoles) of 2N hydrochloric acid is added dropwise to a solution of 0.59 g (1mmole) of compound 3 in 5 ml of ethanol in a 50 ml flask. The reaction mixture isstirred for 18 hours at 50 °C. The solvents are evaporated to dryness, the residue istaken up in dichloromethane (5 ml) and washed with a molar solution of soda (3 x 5ml). After drying the organic phase, filtration and concentration to dryness arecarried out, the oil obtained is purified by chromatography on a column of silica gel(eluent: dichloromethane / methanol: 9 / 1). The pure fractions are collected and afterevaporation under vacuum a beige powder is obtained with a yield of 60%. Meltingpoint: 55-58° C.NMR ]H (400 MHz, DMSO d6, 5): 8.92 (s, 1H, OH); 8.84 (m, 1H, CONH); 7.75 (m,IH, thiophene); 7.63 (m, 1H, thiophene); 7.26 (s, 2H, Ph);7.10 (m, 1H, thiophene); 7.05 (m, 4H, Ph-N); 6.50 (s, 2H, NH2); 4.45 (d, 2H, CH2,J = 5.7 Hz); 3.81 (s, 6H, 2x OCH3).IR: v0H: 3300 cm"1; vc=o (amide): 1630 cm"1; vc=N (amidine): 1590 cm"1.Example 5: 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{4-[2-[(2-thienyl-(imino)methyl)amino]phenyl]ethyl}-benzamide hydroiodide: 55.1) 3,5-bis-(l,l-dimethyIethyI)-4-hydroxy-N-[2-(4-nitrophenyl)ethyl]-benzamide:2.02 g (10 mmoles) of 4-nitrOphenetylamine hydrochloride, 2.5 g (10 mmoles) of3,5-di-fcrt-buty 1-4-hydroxy-benzoic acid, 1.38 ml (10 mmoles) of triethylamine and2.26 g (11 mmoles) of dicyclohexylcarbodiimide are introduced into a 100 ml flaskcontaining 20 ml of THF. The reaction mixture is stirred for 15 hours at ambienttemperature, the precipitate which appears is filtered and rinsed with ethyl acetate.After concentration of the filtrate under reduced pressure, the residue is precipitatedfrom diethyl ether. The solid is recovered by filtration and rinsed with diethyl ether.A white powder is obtained with a yield of 73 %. Melting point: 204-206 °C.NMR 'H (100 MHz, CDC13, 8): 7.52 (s, 2H, Ph); 6.85 (m, 4H, Ph-N02); 6.02 (in,1H, NHCO); 3.62 (m, 2H, ch2-NHCO); 2.82 (m, 2H, CH?-Ph-NO,~): 1.48 (s, 18H,2x tBu).5.2) 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[2-(4-aminophenyl)ethyl]-benzamide:The experimental protocol used is„ the same as that described for intermediate 2.2,with 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[2-(4-nitrophenyl)ethyl]-benzamidereplacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[(4-nitrophenyl)methyl]-benzamide. A white powder is obtained with a yield of 76%. Melting point: 193-195 °C.NMR *H (100 MHz, cdci3, 8): 7.80 (m, 4H, Ph-NH2); 7.55 (s, 2H, Ph);6.10 (m, 1H, NHCO); 5.55 (s, 1H, OH); 3.75 (m, 2H, Ofc-NHCO); 3.10 (m, 2H,CH2-Ph-NH2); 1.50 (s, 18H, 2x tBu).5.3) 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{4-[2-[(2-thienyI(imino)methyl)-amino]phenyl]ethyl}-benzamide hydroiodide: 5_0.78 g (2.74 mmoles) of S-methyl-2-thiophene-thiocarboximide hydroiodide (Ann.Chim. (1962), 7, 303-337) is added to a 50 ml flask containing 1.01 g (2.74 mmoles)of 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[2-(4-aminophenyl)ethyl]-benzamidedissolved in 20 ml of 2-propanol,. The reaction mixture is heated at 40 °C for4 hours. The solvent is evaporated off under vacuum and the residue is precipitatedin the presence of 50 ml of a water / ethyl acetate mixture (1 / 1). The crystals formed.are filtered and washed successively with ethyl acetate and diethyl ether. A paleyellow powder is obtained after drying, with a yield of 68%. Melting point: 185-186 °C.NMR ]H (400 MHz, DMSO d6, 8): 9.80 (s, 1H, NH*); 8.88 (s, 1H, NH+);8.40 (s, 1H, CONH); 8.12 (m, 2H, thiophene); 7.60 (s, 2H, Ph); 7.42 (m, 6H,thiophene, Ph-NH, OH); 3.52 (d, 2H, ch2-NHCO, J = 5.9 Hz); 2.90 (m, 2H, CH2-Ph-NH); 1.40 (s, 18H, 2x tBu).IR: v0h: 3624 cm-1, 3423 cm"1; vc=o (amide): 1636 cm"1;Vc=n (amidine): 1569 cm"1.Example 6: 4-acetoxy-3,5-dimethoxy-N-{4-[2-[(2-thienyI-(imino)methyl)-amino] phenyl] ethyl}-benzamide fumarate: 66.1) 4-acetoxy-3,5-dimethoxy-N-[2-(4-nitrophenyl)ethyl]-benzamide:The experimental protocol used is the same as that described for intermediate 5.1,with 4-acetoxy-3,5-dimethoxy-benzoic acid (intermediate 3.1) replacing 3,5-di-terf-butyl-4-hydroxy benzoic acid. A colourless oil is obtained with a yield of 70 %.The product is used directly in the following stage.6.2) 4-acetoxy-3,5-dimethoxy-N-[2-(4-aminophenyl)ethyl]-benzamide:*The experimental protocol used is the same as that described for intermediate 2.2,with 4-acetoxy-3,5-dimethoxy-N-[2-(4-nitrophenyl)ethyl]-benzamide replacing 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-[(4-nitrophenyl)methyl]-benzamide. Acolourless oil is obtained with a quantitative yield. The product is used directly inthe following stage without additional purification.6.3) 4-acetoxy-3,5-dimethoxy-N-{4-[2-[(2-thienyl(imino)methyI)amino]-phenyl]ethyl}-benzamide fumarate: 6The experimental protocol used to obtain the free base is the same as that describedfor the synthesis of compound 1, with 4-acetoxy-3,5-dimethoxy-N-[2-(4-aminophenyl)ethyl]-benzamide replacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide.The reaction product is salified in the presence of an equimolar quantity of fiimaricacid in ethanol under reflux. Compound 6 is obtained in the form of a beige powderwith a yield of 74%. Melting point: 178-180 °C.NMR fH (400 MHz, DMSO d6, 8): 8.60 (m, 1H, CONH); 7.75 (m, 1H, thiophene);7.64 (d, 1H, thiophene, J = 5.0 Hz); 7.20 (s, 2H, Ph); 7.11 (t, 1H, thiophene,J = 9.0 Hz); 7.02 (m, 4H, Ph-N); 6.61 (s, 2H, CH=CH fumarate); 3.81 (s, 6H,2xoch3); 3.50 (q, 2H, ch2-N, J = 6.5 Hz); 2.82 (t, ch2-PI1, J = 7.0 Hz);2.27 (s, 3H, CH3).IR: vc=o (ester): 1750 cm"1; Vc=o (amide): 1640 cm'1; vc=n (amidine): 1550 cm"1.Example 7: 3,5-dimethoxy-4-hydroxy-N-{4-[2-[(2-thienyI-(imino)methyI)-amino]phenyl]ethyl}-benzamide hydrochloride: 71.40 ml (2.80 mmoles) of a 2N solution of hydrochloric acid is added dropwise, in a50 ml flask, to a solution of 0.64 g (1.37 mmoles) of compound 6 in the form of thefree base in 5 ml of ethanol. The reaction mixture is stirred for 18 hours at 50 °C.The solvents are evaporated to dryness and the evaporation residue is precipitatedfrom a mixture of 5 ml of a 2N solution of soda and 10 ml of dichloromethane.After filtration, the solid is taken up in hydrochloric ethanol (4N). A slightprecipitate is then eliminated. The solvent is evaporated off under reduced pressureand the residue is taken up in acetone. The product 7 precipitates in the form of th ehydrochloride with a yield of 58 %. Melting point: 164-167 °C.NMR lH (400 MHz, DMSO d6, 8): 9.80 (broad s, 1H, NH4); 8.90 (s, 2H, NH+, OH);8.54 (m, 1H, CONH); 8.18 (sv 1H, thiophene); 8.16 (s, 1H, thiophene);7.40 (m, 4H, Ph-N); 7.21 (s, 2H, Ph); 7.11 (m, 1H, thiophene); 3.81 (s, 6H,2x OCH3); 3.51 (q, 2H, CHrN, J = 7.0 Hz); 2.92 (t, CHh-Ph, J = 7.0 Hz).IR: v0h: 3300 cm"1; vc=o (amide): 1620 cm"1; vc=n (amidine): 1560 cm"1.1Example 8: 3,4,5-trihydroxy-N-{4-[2-[(2-thienyl(imino)methyI)-amino]phenyl] ethyl}-benzamide hemi-fumarate: 88.1) 3,4,5-trihydroxy-N-[2-(4-nitrophenyI)ethyl]-benzamide:2 g (11.5 mmoles) of gallic acid, 2.5 g (11.5 mmoles) of 4-nitrophenetylaminehydrochloride, 1.8 g (11.5 mmoles) of hydrated 1-hydroxybenzotriazole, 2.25 g(11.5 mmoles) of l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochlorideand 3.3 ml (23 mmoles) of triethylamine are introduced into a 100 ml flaskcontaining 30 ml of anhydrous DMF. The orange-coloured solution obtained isstirred, at 20 °C, for 20 hours and diluted in a mixture of dichloromethane (50 ml)and water (30 ml). After decantation, the organic phase is washed with a molarsolution of hydrochloric acid (20 ml) and with water (3 x 20 ml) until neutrality isachieved. After drying the organic phase over magnesium sulphate, filtration andconcentration under vacuum, the residue is purified on a column of silica gel (eluent:dichloromethane / methanol: 9 / 1). The expected product is obtained in the form of acolourless oil with a yield of 42 % (1.57 g).NMR 'H (100 MHz, DMSO d6, 8): 8.95 (m, 3H, 3x OH); 7.85 (m, 4H, Ph-N02);6.80 (s, 2H, Ph); 3.36 (m, 2H, CH2-N); 2.97 (t, 2H, Cfo-Ph, J =6.0 Hz).8.2) 3,4,5-trihydroxy-N-[2-(4-aminophenyl)ethyI]-benzamide:The experimental protocol used is the same as that described for intermediate 2.2,with 3,4,5-trihydroxy-N-[2-(4-nitrophenyl)ethyl]-benzamide replacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[(4-nitrophenyl)methyl]-benzamide. A beige powder isobtained with a yield of 89 %. Melting point: 167-169 °C.NMR *H (100 MHz, DMSO d6, 8): 8.80 (m, 3H, OH); 8.07 (t, 1H, NHCO,J = 5.0 Hz); 6.81 (s, 2H, Ph); 6.68 (m, 4H, Ph-NH2); 3.28 (m, 2H, CH2-N);2.60 (t, 2H, Cih-Ph, J =7.0 Hz).8.3) 3,4,5-trihydroxy-N-{4-[2-[(2-thienyl(imino)methyl)amino]-phenyl]ethyl}-benzamide hemi-fumarate: 8The experimental protocol used is the same as that described for compound 1 , with3,4,5-trihydroxy-N-[2-(4-aminophenyl)ethyl]-benzamide replacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide. The base 8 is obtained inthe form of a powder which is salified, by heating under reflux of ethanol, in thepresence of one equivalent of fumaric acid. The salt crystallizes spontaneously at20° C. After filtration and washing with ethanol the expected product is obtained inthe form of a beige powder with a yield of 53 %. Melting point: 245-246 °C.NMR *H (400 MHz, DMSO d6, 8): 8.85 (m, 3H, 3x OH); 8.14 (t, 1H, NHCO,J = 5.0 Hz); 7.73 (s, 1H, thiophene); 7.60 (d, 1H, thiophene, J = 5.0 Hz);7.16 (s, 2H, Ph); 7.09 (t, 1H, thiophene, J = 4.0 Hz); 6.80 (m, 4H, Ph-N);6.59 (broad s, 2H, 1 / 2-CHCH, NH); 3.41 (m, 3H, CH2-N+NH);2.76 (t, 2H, CH2, J = 7.5 Hz).IR: v0h: 3300 cm"1; vc=o (amide): 1620 cm"1; vc=N (amidine): 1590 cm'1.Example 9: N-{4-[4-[3,5-bis-(l,l-dimethylethyl)-4-hydroxybenzoyI]-l-piperazinyl]phenyI}-2-thiophenecarboximidamidehydrochloride: 99.1) 2,6-bis-(l,l-dimethylethyI)-4-{[4-(4-nitrophenyI)-l-piperazinyl]-carbonyl}-phenol:2.07 g (10 mmoles) of l-(4-nitrophenyl)piperazine, 2.5 g (10 mmoles) of 3,5-di-terr-butyl-4-hydroxybenzoic acid and 2.26 g (11 mmoles) of dicyclohexylcarbodiimideare introduced into a 100 ml flask containing 25 ml of DMF. The reaction mixture isstirred for 15 hours at ambient temperature, the precipitates which appears is filteredand rinsed with ethyl acetate. After concentration of the filtrate under reducedpressure, the residue is diluted in 20 ml of ethyl acetate and another insoluble part iseliminated by filtration. The solvent is evaporated off under vacuum and the residueis precipitated from diethyl ether. The solid is filtered, rinsed with 2 x 20 ml of ethylacetate in order to obtain a yellow powder with a yield of 89 %. Meltingpoint: 159.5-160.5 °C.NMR (100 MHz, CDC13, 8): 7.58 (m, 4H, Ph-N02); 7.30 (s, 2H, Ph); 5.50 (s, 1H,OH); 3.85 (m, 4H, piperazine); 3.55 (m, 4H, piperazine); 1.46 (s, 18H, 2x tBu).9.2) 2,6-bis-(l,l-dimethylethyl)-4-{[4-(4-aminophenyI)-l-piperazinyI]-carbonylj-phenol:2.19 g (5.0 mmoles) of intermediate 9.1 is dissolved in 50 ml of absolute ethanol in a250 ml Parr flask in the presence of 10 % Pd / C. The mixture is stirred under 20 PSIof hydrogen, at 30 °C, for one hour. After filtration on celite, the filtrate isconcentrated under vacuum. The evaporation residue is taken up in 25 ml of diethylether, filtered and rinsed with 2 x 20 ml of diethyl ether. A pale pink powder isobtained with a yield of 82%. Melting point: 221-222 °C.NMR'h (100 MHz, cdci3, 8): 7.30 (s, 2H, Ph); 6.75 (m, 4H, Ph-NH2); 5.45 (s, 1H,OH); 9.80 (m, 4H, piperazine); 3.10 (m, 4H, piperazine); 1.49 (s, 18H, 2x tBu).9.3) N-{4-f4-[3,5-bis-(l,l-dimethylethyl)-4-hydroxybenzoyl]-l-piperazinyI]-phenyl}-2-thiophenecarboximidamide hydrochloride: 9The experimental protocol used is the same as that described for compound 1, with2,6-bis-( 1,1 -dimethylethyl)-4- {[4-(4-aminophenyl)-1 -piperazinyl]-carbonyl} -phenolreplacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide.After treatment with a molar solution of HC1 in anhydrous diethyl ether, a beigepowder is obtained with a yield of 75 %. Melting point: 235-236 °C.NMR 'H (400 MHz, DMSO d6, 8): 11.45 (s, 1H, NH+); 9.78 (s, 1H, NH*);8.75 (s, 1H, NH+); 8.19 (m, 2H, thiophene); 7.29 (m, 5H, Ph-N, thiophene);7.10 (s, 2H, Ph); 5.60 (broad s, 1H, OH); 3.70 (m, 4H, piperazine); 3.30 (m, 4H,piperazine); 1.40 (s, 18H, 2x tBu).IR: v0H: 3633 cm"1, 3433 cm"1; vc=0 (amide): 1617 cm"1;Vc=n (amidine): 1590 cm"1.Example 10: N-{4-[4-f3,5-bis-(l,l-dimethylethyl)-4-hydroxybenzyIJ-l-piperazinyl]phenyl}-2-thiophenecarboximidamidehydrochloride: 1010.1) 2,6-bis-(l,l-dimethylethyl)-4-bromomethyIphenol:2.36 g (10 mmoles) of 3,5 di-ter / -butyl-4-hydroxybenzyl alcohol is dissolved in 25ml of anhydrous THF in a 250 ml three-necked flask under a nitrogen atmosphere.The solution is cooled down using an ice bath before the dropwise addition of0.95 ml (10 mmoles) of phosphorus tribromide diluted with 25 ml of anhydrousTHF. After stirring for 15 minutes at 0 °C, the solution is diluted with 100 ml ofdichloromethane and washed with 3 x 30 ml of water followed by 30 ml of saltwater. The organic phase is dried over sodium sulphate, filtered and concentratedunder vacuum in order to produce a brown oil which is used directly in the followi ngstage.10.2) 2,6-bis-(l,l-dimethylethyI)-4-{[4-(4-nitrophenyl)-l-piperazinyI]-methylj-phenol:1.38 g (10 mmoles) of potassium carbonate and 2.07 g (10 mmoles) of l-(4-nitrophenyl)piperazine are added successively to a 100 ml flask containing a solutionof 2.99 g (10 mmoles) of 2,6-bis-(l,l-dimethylethyl)-4-bromomethylphenol in 30 mlof DMF. After stirring for two hours at ambient temperature, the reaction mixture isdiluted with 150 ml of dichloromethane and washed successively with 3 x 40 ml ofwater followed by 40 ml of salt water. The organic solution is dried over sodiumsulphate, filtered and concentrated under reduced pressure. The brown residueobtained is purified on column of silica gel (eluent: petroleum ether (Bp 40-70 °C) / ethyl acetate: 8 / 2). After concentration of the pure fractions, 2.31 g (54%) of abrown powder is obtained. Melting point: 177.5-178.5 °C.NMR *H (100 MHz, CDC13, 8): 7.50 (m, 4H, Ph-N02); 7.12 (s, 2H, Ph); 5.19 (s, 1H,OH); 3.50 (s, 2H, CH2-Ph); 3.49 (m, 4H, piperazine); 2.60 (m, 4H, piperazine);1.49 (s, 18H, 2xtBu).10.3) 2,6-bis-(l,l-dimethylethyl)-4-{[4-(4-aminophenyl)-l-piperazinyl]-methyl}-phenol:The experimental protocol used is the same as that described for intermediate 9.2,with 2,6-bis-(l, l-dimethylethyl)-4- {[[4-(4-nitrophenyl)-l -piperazinylj-carbonyl]-methy 1} -phenol replacing 2,6-bis-(l, 1 -dimethylethyl)-4- {[4-(4-nitrophenyl> 1 -piperazinyl]-carbonyl}-phenol. A pale pink powder is obtained with a yield of75%. Melting point: 152-154 °C.NMR lU (100 MHz, CDC13, 5): 7.12 (s, 2H, Ph); 6.78 (m, 4H, Ph-NH2); 3.59 (s, 2H,CH2-Ph); 3.18 (m, 4H, piperazine); 2.70 (m, 4H, piperazine); 1.47 (s, 18H, 2x tBu).10.4) N-{4-[4-[3,5-bis-(l,l-dimethylethyI)-4-hydroxybenzyl]-l-piperazinyl]-phenyl}-2-thiophenecarboximidamide hydrochloride: _100.43 g (1.5 mmole) of S-methyl-2-thiophene-thiocarboximide hydroiodide (Ami.Chim. (1962), 7, 303-337)is added to a 100 ml flask containing 0.59 g (1.5 mmole)of intermediate 10.3 in 20 ml of 2-propanol. After heating under reflux for 15 hours,the reaction mixture is concentrated to dryness under vacuum. The residue ispurified on a column of silica gel (eluent: dichloromethane / ethanol: 90 / 10). Thepure fractions are concentrated under vacuum and the evaporation residue is salifiedin the presence of a molar solution of HC1 in anhydrous diethyl ether. A pale yellowpowder is obtained with a yield of 40 %. Melting point: 234-236 °C.NMR *H (400 MHz, DMSO d6, 5): 11.60 (s, 1H, NH+); 11.40 (s, 1H, NH+);9.75 (s, 1H, NH4); 8.70 (s, 1H, NH+); 8.17 (m, 2H, thiophene); 7.39 (s, 2H, Ph); 7.38(m, 1H, thiophene); 7.24 (m, 5H, Ph-N, OH); 4.26 (d, 2H, CH2-Ph,J = 4.6 Hz); 3.90 (m, 2H, piperazine); 3.35 (m, 4H, piperazine); 3.15 (m, 2H,piperazine); 1.41 (s, 18H, 2xtBu).<IR: v0h: 3624 cm"1, 3418 cm"1; vc=n (amidine): 1610 cm"1.Example 11: N-{4-[4-[3,5-dimethoxy-4-hydroxybenzoyI]-l-piperazinyl]-phenyl}-2-thiophenecarboximidamide hydrochloride: 1111.1) 2,6-dimethoxy-4-{[4-(4-nitrophenyl)-l-piperazinyI]carbonyI}-phenol:0.99 g (5 mmoles) of syringic acid, 0.74 g (5.5 mmoles) of hydroxybenzotriazole,1.10 g (5.5 mmoles) of dicyclohexylcarbodiimide and 1.04 g (5 mmoles) of l-(4-nitrophenyl)piperazine are dissolved in 10 ml of DMF in a 100 ml flask. Afterstirring for 7 hours at ambient temperature, the mixture is filtered and the precipitaterinsed with 20 ml of DMF followed by 100 ml of chloroform. 2 g of a yellowpowder is obtained which contains approximately 20% of dicyclohexylurea. Theproduct is used as it is in the following stage.NMR (100 MHz, DMSO d6, 5): 7.69 (m, 4H, Ph-N02); 6.88 (s, 2H, Ph);5.72 (m, 1H, OH); 3.91 (s, 6H, 2x OCH3); 3.75 (m, 4H, piperazine);3.49 (m, 4H, piperazine).2 g of intermediate 11.1 is dissolved in 40 ml of absolute ethanol / DMSO (1 / 3) in a250 ml Parr flask in the presence of 10 % Pd / C. The mixture is stirred under 20 PSIof hydrogen, at 25 °C, for 15 hours. After filtration on celite, the filtrate isconcentrated under vacuum. The brown evaporation residue is taken up in 50 ml ofethyl acetate, the precipitate formed is eliminated by filtration, rinsed with 20 ml ofethyl acetate and the filtrate is extracted with 2 x 25 ml of a molar solution of HC1.The aqueous phase is alkalinized by adding sodium carbonate in powder form andextracted with 2 x 50 ml of ethyl acetate. The organic solution is dried over sodiumsulphate, filtered and concentrated under vacuum. The powder obtained is taken upin 20 ml of diethyl ether containing 3 ml of methanol, filtered and rinsed with diethylether. 400 mg (22 % over the two stages) of brown crystals is recovered. Meltingpoint: 182-183 °C.NMR 'H (100 MHz, DMSO d6, 8): 6.80 (s, 2H, Ph); 6.74 (m, 4H, Ph-NH2);4.80 (m, 2H, NH2); 3.91 (s, 6H, 2x OCH3); 3.77 (m, 4H, piperazine);3.08 (m, 4H, piperazine).11.3) N-{4-[4-[3,5-dimethoxy-4-hydroxybenzoylJ-l-piperazinyl]-phenyl}-2-thiophenecarboximidamide hydrochloride: 110.32 g (1.13 mmole) of S-methyl-2-thiophenethiocarboximide hydroiodide (Ann.Chim. (1962), 7, 303-337) is added to a 100 ml flask containing a solution of 0.4 g(1.13 mmole) of intermediate 11.2 in 10 ml of 2-propanol. After heating at 50 °C for15 hours, the reaction mixture is concentrated to dryness under vacuum. Theevaporation residue is then taken up in 100 ml of an ethyl acetate / saturated solutionof sodium carbonate mixture (1 / 1). A precipitate appears which is filtered andrinsed successively with 20 ml of water, 20 ml of ethyl acetate and with 50 ml ofether. The base obtained is salified in the presence of a molar solution of HC1 inanhydrous diethyl ether. After filtration, rinsing with 10 ml of acetone and drying,0.12 g (20%) of a pale yellow powder is recovered. Melting point: 184-185 °C.NMR (400 MHz, DMSO d6, 5): 11.47 (s, 1H, NH^J 9.78 (s, 1H, NH+);8.76 (s, 1H, NH+); 8.18 (m, 2H, thiophene); 7.37 (m, 1H, thiophene); 7.28 (m, 4H,Ph-N); 6.74 (s, 2H, Ph); 4.27 (broad s, 1H, OH); 3.80 (s, 6H, 2x OCH3);3.70 (m, 4H, piperazine); 3.33 (m, 4H, piperazine).IR: v0h: 3423 cm"1; Vc=o (amide): 1610 cm"1; Vc=n (amidine): 1587 cm"1.Example 12: 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyI-N-{4-[(2-thienyl(imino)methyl)amino]phenyl}-2H-l-benzopyran-2-carboxamidehydrochloride: 1212.1) 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(4-nitrophenyl)-2H-l-benzopyran-2-carboxamide:1.62 g (10 mmoles) of l.l'-carbonyl-diimidazole is added to a solution of 2.5 g (10mmoles) of Trolox® in 25 ml of THF in a 100 ml flask. After stirring for one hourat ambient temperature, a solution of 4-nitroaniline in 20 ml of THF is addeddropwise. Stirring is continued for 15 hours and the solvent is evaporated off undervacuum. The residue is diluted in 50 ml of dichloromethane and washedsuccessively with 25 ml of a molar solution of hydrochloric acid, 25 ml of water and25 ml of salt water. The organic phase is dried over sodium sulphate, filtered andconcentrated under reduced pressure. The oil obtained is purified on a column ofsilica gel (eluent: petroleum ether (Bp 40-70 °C) / ethyl acetate: 7 / 3). Afterconcentration of the pure fractions, a pale yellow powder is obtained with a yield of77%. Melting point: 150-151 °C.NMR 'H (100 MHz, cdci3, 5): 8.68 (s, 1H, CONH); 7.91 (m, 4H, Ph);4.59 (s, 1H, OH); 2.95-0.87 (m, 16H, Trolox®).12.2) 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(4-aminophenyl)-2H-l-benzopyran-2-carboxamide:The experimental protocol used is the same as that described for intermediate 9.2,with 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(4-nitrophenyl)-2H-1 -benzopyran-2-carboxamide replacing 2,6-bis-( 1,1 -dimethylethyl)-4- {[4-(4-nitrophenyl)-l-piperazinyl]-carbonyl}-phenol. The reaction product is purified on acolumn of silica gel (eluent: petroleum ether (Bp 40-70° C) / ethyl acetate: 6 / 4). Thepure fractions are collected, after evaporation of the solvent under vacuum, acolourless oil is obtained with a yield of 45 %.NMR 'H (100 MHz, CDC13, 5): 8.19 (s,lH, CONH); 7.00 (m, 4H, Ph);4.59 (s, IH, OH); 3.65 (broad s, 2H, NH2); 2.95-0.87 (m, 16H, Trolox®).12.3) 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyI-N-{4-[2-thienyl(iminomethyl)amino]phenyl}-2H-l-benzopyran-2-carboxamidehydrochloride: 12The experimental protocol used is the same as that described for compound 1, with3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(4-aminophenyl)-2H-l-benzopyran-2-carboxamide replacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide. Melting point: 279-280 °C.NMR 'H (400 MHz, DMSO d6, 8): 9.80 (s, 1H, NH+); 9.50 (s, 1H, NH+);8.73 (s, 1H, NHCO); 8.18 (m, 2H, thiophene); 7.60 (s, 1H, OH); 7.59 (m, 4H, Ph);7.36 (m, 1H, thiophene); 2.60-1.57 (m, 16H, Trolox®).IR: V0h: 3236 cm"1; Vc=o (amide): 1683 cm"1; vc=N (amidine): 1577 cm"1.Example 13: N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyI-2H-l-benzopyran-2-yl)-carbonyI]-l-piperazinyI]phenyl}-2-thiophenecarboximidamide hydrochloride: 1313.1) 3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-nitrophenyl)-l-piperazinyl]-carbonyl}-2H-l-benzopyran-6-oI:1.62 g (10 mmoles) of l.l'-carbonyl-diimidazole is added to a solution of 2.5 g (10mmoles) of Trolox® in 25 ml of THF in a 100 ml flask. After stirring for one hourat ambient temperature, a solution of l-(4-nitrophenyl)piperazine in 10 ml of DMF i sadded dropwise. Stirring is continued for 15 hours, the reaction mixture is thenconcentrated under vacuum. The evaporation residue is dissolved in 50 ml ofdichloromethane and washed successively with 3 x 25 ml of water and 25 ml of saltwater. The organic phase is dried over sodium sulnhate filtered and rnnrpntrateHunder reduced pressure. The oil obtained is precipitated from 30 ml of an ethylacetate / methanol mixture (95 / 5), the solid is filtered and washed with 2 x 20 ml ofethyl acetate. A pale yellow powder is obtained with a yield of 79 %. Meltingpoint: 199-200 °C.NMR 'H (100 MHz, cdci3, 8): 7.45 (m, 4H, Ph); 4.41-3.35 (m, 8H, piperazine);2.95-1.25 (m, 16H, Trolox®).13.2) 3,4-dihydro-2,5,7,8-tetramethyI-2-{4-[(4-aminophenyl)-l-piperazinyl]-carbonyl}-2H-l-benzopyran-6-ol:The experimental protocol used is the same as that described for intermediate 2 ,2,with 3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-nitrophenyl)-l-piperazinyl]-carbonyl} -2H-1 -benzopyran-6-ol replacing 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-[(4-nitrophenyl)methyl]-benzamide. The reaction product is purified on a columnof silica gel (eluent: dichloromethane / methanol: 9 / 1). The pure fractions arecollected in order to produce, after evaporation of the solvent under vacuum, abrown oil with a yield of 66 %.NMR lH (100 MHz, cdci3, 5): 6.70 (m, 4H, Ph); 4.15-2.97 (m, 8H, piperazine);2.80-0.90 (m, 18H, Trolox®).13.3) N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)-carbonyl]-l-piperazinyI]phenyl}-2-thiophenecarboximidamidehydrochloride: 13The experimental protocol used is the same as that described for compound t, with^,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-aminophenyl)-l-piperazinyl]-carbonyl}-2H-1 -benzopyran-6-ol replacing 3,5 -bis-( 1,1 -dimethylethyl)-4-hydroxy-N-(4-amino-phenyl)-benzamide. However, the reaction is slower and requires heating far15 hours. The base obtained after extraction is purified on a column of silica gel(eluent: petroleum ether (Bp 40-70 °C) / ethyl acetate: 3 / 7). The pure fractions areconcentrated under vacuum and the evaporation residue is salified in the presence ofa molar solution of HC1 in anhydrous diethyl ether. A pale yellow powder isobtained with a yield of 40 %. Melting point: 210-211 °C.NMR *H (400 MHz, DMSO d6, 5): 11.50 (s, 1H, NH+); 9.79 (s, 1H, NH+);8.69 (s, 1H, NH+); 8.19 (m, 2H, thiophene); 7.38 (m, 1H, thiophene); 7.20 (m, 4H,Ph); 4.58 (broad s, 1H, OH); 4.11 (m, 2H, piperazine); 3.61 (m, 2H, piperazine);3.19 (m, 4H, piperazine); 2.62-1.55 (m, 16H, Trolox®).IR: v0h: 3410 cm'1; vc=o (amide): 1642 cm'l; vc=n (amidine): 1613 cm"1.Example 14: N-{4-[4-[(5 methoxy-lH-indol-3-yl)methylcarbonyl]-l-piperazinyl]phenyl}-2-thiophenecarboximidamide: 1414.1) l-[(5-methoxy-lH-indol-3-yl)methylcarbonyl]-4-(4-nitrophenyl)-piperazine:1.62 g (10 mmoles) of l.l'-carbonyl-diimidazole is added to a solution of 2.05 g (10mmoles) of 5-methoxyindole-3-acetic acid in 10 ml of THF in a 100 ml flask. Afterstirring for one hour at ambient temperature, a solution of l-(4-nitrophenyl)piperazine in 10 ml of DMF is added dropwise. Stirring is continued for15 hours. The reaction mixture is then concentrated under vacuum and theevaporation residue is precipitated from 50 ml of an ethyl acetate / water mixture(1 / 1). After filtration, the solid is rinsed successively with 50 ml of water, 50 ml ofethyl acetate and 50 ml of dichloromethane. A yellow powder is obtained, afterdrying under vacuum, with a yield of 91 %. Melting point: 239-240 °C.NMR 'H (100 MHz, DMSO d6, 8): 10.90 (m, 1H, NH); 7.63 (m, 4H, Ph-N02);7.40-7.15 (m, 3H, indole); 6.87 (dd, 1H indole, Jortho = 8.7 Hz, Jmeta= 2.8 Hz); 3.90(s, 2H, CH2-CO); 3.88 (s, 3H, OCH3); 3.79 (m, 4H, piperazine);3.50 (m, 4H, piperazine).14.2) l-[(5 methoxy-lH-indol-3-yl)methyIcarbonyl]-4-(4-aminophenyl)-piperazine:1 g (2.53 mmoles) of intermediate 14.1 is dissolved in 30 ml of DMSO in a 250 mlParr flask in the presence of 10% Pd / C. The mixture is stirred under 20 PSI ofhydrogen, at 25°C, for 7 hours. After filtration on celite, the filtrate is concentratedunder vacuum. The evaporation residue is diluted in 50 ml of ethyl acetate andwashed with 3 x 50 ml of water. The organic phase is then extracted with 2 x 25 mlof a molar solution of HC1. After having washed the acid solution with 2 x 25 ml ofethyl acetate, it is alkalinized with sodium carbonate in powder form. Once theproduct is reextracted with 2 x 50 ml of ethyl acetate, the organic solution is driedover sodium sulphate, filtered and the solvent evaporated off under vacuum. Theresidue is purified on a column of silica gel (eluent: dichloromethane / methanol:98 / 2). The pure fractions are collected and after evaporation of the solvent underreduced pressure, 0.39 g of a pale yellow powder is obtained with a yield of 46 %.Melting point: 119-120° G.NMR 'H (100 MHz, cdci3, 8): 8.32 (s, 1H, NH indolic); 7.27-6.80 (m, 4H, indole);6.69 (m, 4H, Ph-NH2); 3.82 (s, 3H, OCH3); 3.80 (s, 2H, CH2-CO);3.80 (m, 2H, piperazine); 3.62 (m, 2H, piperazine); 3.48 (s, 2H, NH2);2.90 (m, 4H, piperazine).14.3) N-{4-[4-[(5 methoxy-lH-indoI-3-yl)methylcarbonyl]-1-piperazinyl]phenyI}-2-thiophenecarboximidamide: 14The experimental protocol used is the same as that described for compound 1, withl-[(5 methoxy-lH-indol-3-yl)methylcarbonyl]-4-(4-aminophenyl)-pipera2:inereplacing 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzami;de.The expected product is isolated in the form of the free base with a yield of 20 %(pale yellow powder). Melting point: 221-222 °C.NMR 'H (400 MHz, DMSO d6, 5): 10.78 (s, 1H, indolic NH);7.72 (m, 1H, thiophene); 7.59 (m, 1H, thiophene); 7.22 (d, 1H, indole, J = 8.7 Hz);7.19 (m, 1H, thiophene); 7.09 (m, 2H, indole); 6.82 (m, 4H, Ph); 6.72 (m, 1Hindole); 6.35 (s, 2H, NH2); 3.80 (s, 2H, CH2); 3.73 (s, 3H, CH3); 3.62 (m, 4H,piperazine); 2.95 (m, 4H, piperazine).IR: v0H: 3414 cm"1; vc=0 (amide): 1628 cm"1; vc=N (amidine): 1590 cm"1.Example 15: N-[4-[4-[{3-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-l-oxo-2-propenyl}-l-piperazinyl]-phenyl]]-2-thiophenecarboximidamide fumarate: 1515.1) 2,6-bis-(l,l-dimethyIethyl)-4-{3-[4-(4-nitrophenyl)-l-piperazinyl]-3-oxo-2-propenyl}-phenol:The experimental protocol used is the same as that described for intermediate 11.1,with 3,5-di-ferf-buty 1-4-hydroxycinnamic acid replacing syringic acid. An oil isobtained with a yield of 60 %.NMR 'H (100 MHz, CDC13, 5): 7.71 (d, 1H, C=CH, J = 15.0 Hz); 7.51 (m, 4H,Ph-N02); 7.38 (s, 2H, Ph); 6.69 (d, 1H, HC=C, J = 15.0 Hz); 5.50 (s, 1H, OH);3.88 (m, 4H, piperazine); 3.53 (m, 4H, piperazine); 1.47 (s, 18 H, 2x tBu).15.2) 2,6-bis-(l,l-dimethyIethyl)-4-{3-[4-(4-aminophenyl)-l-piperazinyIJ-3-oxo-2-propenyl}-phenoI:0.5 g (1 mmole) of intermediate 15.1 is dissolved in 5 ml of concentratedhydrochloric acid and 5 ml of absolute ethanol in a 50 ml flask equipped with acondenser. The mixture is cooled down to 0 °C and 1.69 g (7.5 mmoles) of tinchloride (dihydrate) is added in several portions. At the end of the addition, thereaction medium is heated under reflux for 30 minutes. The solvents are thenevaporated off under vacuum, the residue is taken up in 15 ml of water, neutralizedwith 2N soda and diluted with 20 ml of dichloromethane. The precipitate obtained isfiltered on celite and the filtrate is decanted. The organic phase is dried over sodiumsulphate, filtered and concentrated under reduced pressure in order to obtain 0.3 g(67 %) of a yellow oil.NMR 'H (100 MHz, CDC13, 5): 7.66 (d, 1H, OCH, J = 15.0 Hz); 7.37 (s, 2H, Ph);6.75 (m, 4H, Ph-NH2); 6.30 (d, 1H, HC=C, J = 15.0 Hz); 5.46 (s, 1H, OH); 3.80 (m,4H, piperazine); 3.06 (m, 4H, piperazine); 1.46 (s, 18 H, 2x tBu).15.3) N-[4-[4-[{3-[3,5-bis-(l,l-dimethylethyl)-4-hydroxy-phenyl]-l-oxo-2-propenyl}-l-piperazinyl]-phenyI]]-2-thiophenecarboximidamidefumarate: 15The experimental protocol used is the same as that described for compbund 1, with2,6-bis-( 1,1 -dimethylethyl)-4- {3-[4-(4-aminophenyl)-1 -piperazinyl]-3-oxo-2-propenyl} -phenol replacing 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-(4-taminophenyl)-benzamide.The reaction product is salified in the presence of an equimolar quantity of fumaricacid in ethanol under reflux. Compound 15 is obtained in the form of a yellowpowder with a yield of 22%. Melting point: 170.5-173 °C.NMR XH (400 MHz, DMSO d6, 8): 7.77 (s, 1H, thiophene); 7.67 (d, 1H, thiophene,J = 5.0 Hz); 7.48 (d, 1H, C=CH, J = 15.0 Hz); 7.39 (s, 2H, Ph); 7.34 (broad s, 1H,OH); 7.13 (t, 1H, thiophene, J= 4.0 Hz); 7.05 (d, 1H, HC=C, J = 15.0 Hz); 6.92 (m,4H, Ph-N); 6.60 (s, 2H, CH=CH fumarate); 3.78 (m, 4H, piperazine); 3.13 (m, 4H,piperazine); 1.41 (s, 18 H, 2xtBu).IR: vOH: 3619 cm"1, 3300 cm"1; vc=o (amide): 1640 cm"1: vc=c: 1600 cm"1; vc=n(amidine): 1570 cm"1.Example 16: 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{3-[[(2-thienyl-(imino)methyl)amino]phenyl]methyI}-benzamidehydrochloride: 1616.1) 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[(3-nitrophenyl)methyl]-benzamide:The experimental protocol used is the same as that described for intermediate 2.1,with 3-nitrobenzylamine hydrochloride replacing 4-nitrobenzylamine hydrochloride.A white powder is obtained with a yield of 63 %. Melting point: 210-211 °C.NMR 'H (100 MHz, DMSO, 8): 9.12 (m, 1H, NH); 8.25 (m, 2H, Ph-N02); 7.80 (m,4H, Ph-N02 + Ph-OH); 7.60 (broad s, 1H, OH); 4.68 (d, 2H, CH2, J = 6 Hz); 1.55 (s,18H, 2 x tBu).16.2) 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[(3-aminophenyI)methyl]-benzamide:2.40 g (6.2 mmoles) of 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[(3-nitrophenyl)methyl]-benzamide is dissolved in 45 ml of an absolute ethanol / TKOFmixture (1 / 2) in a 250 ml Parr flask, in the presence of 10 % Pd / C. The mixture isstirred under 20 PSI of hydrogen, at 30 °C, for three hours. After filtration on celite,the filtrate is concentrated to dryness and the residue is purified on a silica column(eluent: heptane / ethyl acetate: 60 / 40). The pure fractions are collected andconcentrated under reduced pressure in order to produce 0.94 g (45%) of a whitepowder. Melting point: 171-172 °C.NMR *H (100 MHz, CDC13, 5): 7.20 (m, 2H, Ph-NH2); 6.70 (m, 4H, Ph-NH2 +Ph-OH); 6.34 (m, 1H, NH); 5.55 (s, 1H, OH); 4.56 (d, 2H, CH2, J = 6 Hz);3.70 (broad s, 2H, NH2); 1.49 (s, 18H, 2 x tBu).16.3) 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{3-[[(2-thienyl-(imino)methyl)-amino]phenyl]methyl}-benzamide hydrochloride: 16The experimental protocol used is the same as that described for compound 1, with3,5-bis-(l,l -dimethy lethy l)-4-hy droxy-N- [(3 -aminophenyl)methy 1] -benzamidereplacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide.After salification with a molar solution of HC1 in an acetone / anhydrous methanolmixture, a pale yellow powder is obtained with a yield of 50 %. Melting point: 226-227 °C.NMR *H (400 MHz, DMSO d6, 5): 11.71 (s, 1H, NH+); 9.93 (s, 1H, NH);9.10 (s, 1H, CONH); 9.00 (s, 1H, NH4); 8.18 (m, 2H, thiophene); 7.70 (s, 2H, Ph);7.42 (m, 6H, thiophene, Ph-NH, OH); 4.50 (d, 2H, ch2-NHCO, J = 5.4 h2:);1.40 (s, 18H, 2 xtBu).ir: v0h: 3420 cm"1; vc=o (amide): 1639 cm"1; vc=n (amidine): 1578 cm"1.Example 17: N-[3,5-bis-(l,l-dimethyIethyl)-4-hydroxyphenyll-N'-{{4-[(2-thienyl(imino)methyl)amino]phenyl}methyl}-ureahydrochloride: 1717.1) 4-amino-2,6-bis-(l,l-dimethylethyl)-phenol:3.6 g (14 mmoles) of 4-nitro-2,6-bis-(l,l-dimethylethyl)-phenol (J. Org. Chem.(1968), 33 (1), 223-226) is dissolved in 60 ml of an ethanol and dichloromethanemixture (2 / 1) in a 250 ml Parr flask, in the presence of a catalytic quantity of 10 %Pd / C. The mixture is stirred for 2 hours, at 20 °C, under 20 PSI of hydrogen. Afterfiltration on celite, the filtrate is concentrated to dryness under reduced pressure.The reddish brown powder obtained is suspended in heptane (30 ml), filtered andrinsed with the same volume of heptane. The expected product is obtained in theform of a salmon pink powder with a yield of 50 % (1.56 g). Melting point: 123-124 °C.NMR !H (100 MHz, cdci3, 8): 6.60 (s, 2H, Ph); 4.65 (broad s, 1H, OH);3.15 (broad s, 2H, NH2); 1.42 (s, 18H, 2x tBu).17.2) 4-nitrophenylacetic acid chloride:t3.75 ml (7.5 mmoles) of a 2M solution of oxalyl chloride in dichloromethane isadded at 20 °C, to a solution of 0.9 g (5 mmoles) of 4-nitrophenylacetic acid in amixture comprising 10 ml of dichloromethane and 0.5 ml of DMF. After stirring for30 minutes, the solution is concentrated under vacuum. The yellow oil obtained isused without additional purification in the following stage.17.3) 4-nitrobenzylisocyanate:4-nitrophenylacetic acid chloride in solution in dry acetone (7.5 ml)is added slowlyto an aqueous solution of 0.75 g (11.5 mmoles) of sodium azide, cooled down to0 °C. The medium is stirred for one hour after the end of the addition, at 0-5 °C.The reaction medium is then diluted with 30 ml of chloroform, decanted and theorganic phase is washed with water (20 ml) followed by a saturated solution ofsodium chloride (20 ml). After drying over sodium sulphate, the organic solution isfiltered and partially concentrated (~ 20 ml) under vacuum.This solution of the acylazide in chloroform is then heated, under reflux, for onehour. The isocyanate obtained is used directly, in solution, in the following stage.17.4) N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-[(4-nitrophenyl)methyl]-urea:1.1 g (5 mmoles) of 4-amino-2,6-bis-(l,l-dimethylethyl)-phenol is added in oneportion to a solution of the isocyanate (intermediate 17.3) (5 mmoles theoretical) in20 ml of chloroform. After stirring for 2 hours, at 20 °C, the precipitate whichappears is filtered and rinsed with chloroform (2 x 20 ml). A yellow powder isobtained with a yield of 72 %. Melting point: 240-241 °C.NMR 'H (100 MHz, DMSO d6, 8): 8.60 (s, 1H, NH-Ph); 8.01 (m, 4H, Ph-NO:!);7.30 (s, 2H, Ph-OH); 6.77 (m, 1H, NH-CH2); 6.71 (s, 1H, OH); 4.52 (d, 2H, CH2, J =5.5 Hz); 1.49 (s, 18H,2xtBu).17.5) N-[(4-aminophenyl)methyI]-N'-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-urea:0.55 g (1.38 mmole) of N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-[(4-nitrophenyl)methyl]-urea is dissolved in an ethanol and ethyl acetate mixture (2 / 1),in a 100 ml autoclave, in the presence of 10% Pd / C. After hydrogenation for onehour and 30 minutes, at 20 °C, under 20 PSI, the mixture is filtered on celite and thefiltrate is concentrated under vacuum. The evaporation residue is diluted in 20 ml ofdiethyl ether and the expected product crystallizes spontaneously. The crystals airefiltered and rinsed with 20 ml of diethyl ether. A white powder is obtained with ayield of 60 % (0.31 g). Melting point: 194-195 °C.NMR 'H (100 MHz, CDC13, 8): 7.08 (s, 2H, Ph-OH); 6.87 (m, 4H, Ph-NH2); 6.15 (s,1H, NH-Ph); 5.14 (s, 1H, OH); 4.89 (m, 1H, NH-CH2); 4.41 (d, 2H, CH2, J = 5.5Hz); 3.65 (broad s, 2H, NH2); 1.40 (s, 18H, 2x tBu).17.6) N-(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-{{4-[2-thienyl(imino-methyl)amino]phenyI}methyl}-urea hydrochloride: 17The experimental protocol used is the same as that described for compound 1, withN-[(4-aminophenyl)methyl]-N '-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl]-ureareplacing 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-(4-amkophenyl)-benzamide.After salification by a molar solution of HC1 in anhydrous diethyl ether, a whitepowder is obtained with a yield of 45 %. Melting point: 236-237 °C.NMR [H (400 MHz, DMSO d6, 8): 11.42 (broad s, 1H, NH4); 9.77 (broad s, 1H,NH4); 8.92 (broad s, 1H, NH4); 8.54 (s, 1H, NH-Ph); 8.11 (m, 2H, thiophene); 7.41(m, 5H, Ph-N, thiophene); 7.19 (s, 2H, Ph); 6.70 (m, 1H, NH-CH2); 6.60 (s, 1H,OH); 4.35 (d, 2H, CH2, J = 5.5 Hz); 1.34 (s, 18H, 2x tBu).IR: V0h'. 3624 cm"1; Vc=o (urea): 1644 cm"1; Vc=n (amidine): 1569 cm"1.Example 18: N-[5-[{3-(3,5-bis-(l,l-dimethylethyI)-4-hydroxyphenyl)-l-oxo-2-propenyl}-amino]-2-hydroxyphenyI]-2-thiophenecarboximidamide hydrochloride: 1818.1) 3-[(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N-(4-hydroxy-3-nitrophenyl)-2-propenamide:1.78 g (6.4 mmoles) of 3,5-di-ter / -butyl-4-hydroxycinnamic acid, 0.99 g (6.4mmoles) of 4-amino-2-nitrophenol, diluted beforehand in 10 ml of DMF, 0.86 g (6.4mmoles) of hydroxybenzotriazole and 1.32 g (6.4 mmoles) ofdicyclohexylcarbodiimide are introduced into a 50 ml flask containing 10 ml ofTHF. The reaction mixture is stirred for 15 hours at ambient temperature, the:precipitate which appears is filtered and rinsed with ethyl acetate. Afterconcentration of the solution under reduced pressure, the residue is diluted in 20 mlof ethyl acetate and the insoluble part is filtered again. The filtrate is washed with20 ml of a saturated solution of sodium carbonate followed by 20 ml of water and 20ml of a saturated solution of sodium chloride. After drying over sodium sulphate,the organic solution is filtered and concentrated to dryness under reduced pressure.The residue is purified on a silica column (eluent: heptane / ethyl acetate: 8 / 2). Thepure fractions are collected and concentrated under vacuum in order to produce 1.95g (47 %) of expected compound in the form of a yellow-orange powder. Meltingpoint: 231-232 °C.NMR 'H (100 MHz, cdci3, 8): 10.45 (s, 1H, NH); 8.45 (d, 1H, Ph-N02,J = 1.7 Hz); 7.98 (dd, 1H, Ph-N02, I = 1.7 Hz and J = 6.8 Hz); 7.78 (d, 1H, -CH=CH-, J = 10.5 Hz); 7.75 (s, 1 H, OH); 7.40 (s, 2H, Ph-OH); 7.20 (d, 1H, Ph-N02); 6.48 (d, 1H, -CH=CH-); 5.51 (s, 1H, OH); 1.50 (s, 18H, 2 x tBu).18.2) 3-[(3,5-bis-(l,l-dimethylethyI)-4-hydroxyphenyl]-N-(4-hydroxy-3-aminophenyl)-2-propenamide:0.9 g (2.18 mmoles) of 3-[(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N-(4-hydroxy-3-nitrophenyl)-2-propenamide is dissolved in 20 ml of ethyl acetate in. a100 ml flask surmounted by a condenser, 2.46 g (10.9 mmoles) of tin chloride(dihydrate) is added and the mixture is heated at 70 °C for three hours. Afterreturning to ambient temperature, the reaction medium is poured into a stirredsolution of sodium bicarbonate (0.1 M), a precipitate forms, which is eliminated byfiltration on celite. The filtrate is decanted and the aqueous phase is extracted with20 ml of ethyl acetate. The phases organic are combined and washed with 20 ml ofwater followed by 20 ml of a saturated solution of sodium chloride. After dryingover sodium sulphate and filtration, the organic solution is concentrated to dryness,under partial vacuum. The evaporation residue is suspended in a heptane / ethylacetate mixture (1 / 1) and filtered in order to produce a yellowish powder with ayield of 53 %. The product is used as it is in the following stage.18.3) N-[5-f{3-(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl)-l-oxo-2-propenyI}amino]-2-hydroxyphenyl]-2-thiophenecarboximidamidehydrochloride: 18The experimental protocol used is the same as that described for compound 1, with3 - [(3,5 -bis-( 1,1 -dimethy lethyl)-4-hydroxyphenyl]-N-(4-hydroxy-3 -aminopheny 1)-2-propenamide replacing 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide. The free base is purified on a silica column (elueni::heptane / ethyl acetate: 35 / 65). The pure fractions are collected and concentratedunder reduced pressure. The evaporation residue is diluted in 10 ml of acetone andsalified by a molar solution of HC1 in the anhydrous ether, as described previously.Finally 0.35 g (62%) of a yellow powder is obtained. Melting point: 199-200 °C.NMR 'H (400 MHz, DMSO, 5): 11.11 (s, 1H, NH4); 10.29 (s, 1H, NH+);10.17 (s, 1H, NH4); 9.71 (s, 1H, CONH); 8.61 (broad s, 1H, OH); 8.14 (m, 2H,thiophene); 7.79 (s, 1H, Ph-N); 7.53 (m, 1H, Ph-N); 7.48 (d, 1H, -CH=CH-, J = 14.7Hz); 7.37 (m, 4H, Ph-tBu + OH + Ph-N); 7.05 (m, 1H, thiophene);6.68 (d, 1H, -CH=CH-); 1.41 (s, 18H, 2 x tBu).IR: v0h: 3624 cm"1, 3415 cm"1; Vc=0 (amide): 1656 cm"1; vc=c: 1616 cm"1; vc=n(amidine): 1587 cm"1.Example 19: N-[3-[{3-(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl)-l-oxo-2-propenyI}-amino]-4-hydroxyphenyl]-2-thiophenecarboximidamide hydrochloride: 1919.1) 3-[(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N-(2-hydroxy-5-nitrop heityl)-2-propenamide:The experimental protocol used is the same as that described for intermediate 18.1, .with 2-amino-4-nitrophenol replacing 4-amino-2-nitrophenol. A light yellowpowder is obtained with a yield of 25 %. Melting point: 256-257 °C.NMR 'H (400 MHz, DMSO, 8): 11.79 (broad s, 1H, OH); 9.59 (s, 1H, NH);9.21 (broad s, 1H, Ph-N02); 7.90 (dd poor resolution, 1H, Ph-N02, J = 8.1 Hz);7.52 (d, 1H, -CH=CH-, J = 15.5 Hz); 7.47 (s, 1H, OH); 7.42 (s, 2H, Ph-OH); 7.15 (d,1H, -CHCH-); 7.04 (d, 1H, Ph-N02); 1.42 (s, 18H, 2 x tBu).19.2) 3-[(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N-(2-hydroxy-5-aminophenyl)-2-propenamide:The experimental protocol used is the same as that described for intermediate 18.2, .with 3 -[(3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl]-N-(2-hydroxy-5-nitrophenyl)-2-propenamide replacing 3 -[(3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl]-N-(4-hydroxy-3-nitrophenyl)-2-propenamide . A yellow powderis obtained with a yield of 74 %. The product is used without additional purificationin the following stage.1,9.3) N-[5-[{3-(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyI)-l-oxo-2-propenyl}-amino]-2-hydroxyphenyl]-2-thiophenecarboximidamidehydrochloride: 19The experimental protocol used is the same as that described for compound 1, with3-[(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N-(2-hydroxy-5-aminophenyl)-2-propenamide replacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide. After salification by a molar solution of HCl inanhydrous diethyl ether, a yellow powder is obtained with a yield of 54 %. Meltingpoint: 256-257 °C.NMR 'H (400 MHz, DMSO d6, 8): 11.32 (s, 1H, NH+); 10.67 (s, 1H, NH4); 9.69 (s,1H, NH+); 9.55 (s, 1H, CONH); 8.70 (broad s, 1H, OH); 8.19 (m, 2H, thiophene);7.48 (d, 1H, -CH=CH-, J = 15.5 Hz); 7.40 (s, 2H, Ph-tBu);7.37 (m, 2H, Ph-N); 7.34 (s, 1H, OH); 7.13 (d, 1H, -CHCH-); 7.10 (m, 1H, Ph-N);6.99 (m, 1H, thiophene); 1.41 (s, 18H, 2 x tBu).IR: V0h; 3623 cm*1, 3410 cm"1; Vc=o (amide): 1652 cm"1' vc=c: 1616 cm'1; vD=N(amidine): 1587 cm"1.Example 20: N-{4-[4-[3,4,5-trihydroxybenzoyl]-l-piperazinyl]phenyI}-2-thiophenecarboximidamide hydrochloride: 2020.1) 5-{[4-(4-nitrophenyl)-l-piperazinyl]carbonyl}-benzene-l,2,3-trioI:The experimental protocol is the same as that described for intermediate 8.1, withl-(4-nitrophenyl)piperazine replacing 4-nitrophenetylamine. A yellow powder isobtained which also contains a trace of impurities with a yield of 43 %.NMR 'H (100 MHz, DMSO, 8): 9.17 (broad s, 2H, 2x -OH); 8.55 (broad s, 1H, -OH); 7.57 (m, 4H, Ph-N02); 6.40 (s, 2H, Ph-OH); 3.59 (m poor resolution, 8 H,piperazine).20.2) 5-{[4-(4-aminophenyl)-l-piperazinyl]carbonyl}-benzene-l,2,3-triol:The experimental protocol used is the same as that described for intermediate 2.2,with 5- {[4-(4-nitrophenyl)-1 -piperazinyl]carbonyl}-benzene-1,2,3-triol replacing3,5-bis-(l, l-dimethylethyl)-4-hydroxy-N-[(4-nitrophenyl)methyl]-benzamide. Abeige powder is obtained with a yield of 61 %. This is used directly in the followingstage without additional purification.NMR !H (100 MHz, DMSO, 8): 9.12 (broad s, 2H, 2x -OH); 8.55 (broad s, 1H,-OH); 6.61 (m, 4H, Ph-NH2); 6.34 (s, 2H, Ph-OH); 3.59 (m, 4H, piperazine); 2.89(m, 4H, piperazine).t20.3) N-{4-[4-[3,4,5-trihydroxybenzoyl]-l-piperazinyl]phenyl}-2-thiophenecarboximidamide hydrochloride: 20The experimental protocol used is the same as that described for compound 1, with5-{[4-(4-aminophenyl)-1 -piperazinyl]carbonyl}-benzene-1,2,3-triol replacing 3,5-bis-(l, 1 -dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide. After treatmentwith a molar solution of HC1 in anhydrous diethyl ether, a brown powder is obtainedwith a yield of 25 %. Melting point: 198-205 °C.NMR 'H (400 MHz, DMSO d6, 8): 11.38 (s, 1H, NH4); 9.75 (s, 1H, NH"1);9.00 (broad s, 1H, OH); 8.75 (s, 1H, NH"1); 8.15 (m, 2H, thiophene); 7.39 (m, 1H,thiophene); 7.22 (m, 4H, Ph-N); 6.40 (s, 2H, Ph); 5.11 (broad s, 2H, 2 x OH);3.65 (m, 4H, piperazine); 3.29 (m, 4H, piperazine).IR: V0h: 3399 cm",: Vc=o (amide): 1696 cm"I; Vc=N (amidine): 1588 cm'1.Example 21: N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenylj-N'-{{4-[(2-thienyl(imino)methyl)amino]phenyI}carbonyIamino}-urea hydrochloride: 21.21.1) N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-[(4-nitrophenyl)-carbonylamino]-urea:0.22 g (0.73 mmole) of triphosgene at 20 °C is dissolved, under an argonatmosphere, in a 50 ml three-necked flask equipped with a dropping funnel. Asolution of 0.44 g (2 mmoles) of 4-amino-2,6-bis-(l,l-dimethylethyl)-phenoI(intermediate 17.1) and 0.38 ml (2.2 mmoles) of diisopropylethylamine in 7 ml ofanhydrous dichloromethane is added dropwise to this mixture over one hour. Fiveminutes after the end of the addition, a solution of 0.36 g (2 mmoles) of 4-nitrobenzoyl-hydrazide and 0.38 ml (2.2 mmoles) of diisopropylethylamine in 4 mlof anhydrous DMF is added in a single portion. After stirring for four hours at20 °C, the reaction mixture is concentrated to dryness under reduced pressure. Theevaporation residue is diluted in 40 ml of ethyl acetate and the organic solution iswashed successively with 3 times 20 ml of water and 20 ml of a saturated solution ofsodium chloride. After drying over sodium sulphate, the organic solution is filtered,and the filtrate concentrated to dryness under reduced pressure. The residueobtained is suspended in heptane, stirred and filtered in order to produce a yellowpowder with a yield of 86 %.Melting point: 163-164 °C.NMR *H (100 MHz, DMSO d6, 8): 10.65 (broad s, 1H, NH amide); 8.72 (s, 1H,NH-Ph); 8.38 (m, 4H, Ph-N02); 8.20 (s, 1H, CO-NH-NH); 7.36 (s, 2H,Ph-OH); 6.78 (s, 1H, OH); 1.50 (s, 18H, 2 x tBu).21.2) N-[(4-aminophenyl)carbonylaminoJ-N'-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-urea:0.72 g (1.68 mmoles) of N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-[(4-nitrophenyl)carbonylamino]-urea is dissolved in 30 ml of absolute ethanol in a 250ml Parr flask in the presence of 10 % Pd / C. The mixture is stirred under 20 PSI ofhydrogen, at 30 °C, for two hours. After filtration on celite, the filtrate isconcentrated under vacuum. The evaporation residue is suspended in diethyl ether(20 ml) stirred and filtered in order to produce a pale yellow powder with a yield of75%. Melting point: 245-246 °C.NMR *H (100 MHz, DMSO d6, 8): 9.84 (broad s, 1H, NH amide); 8.56 (s, 1H, NH-Ph); 7.85 (m, 2H, Ph-NH2); 7.74 (s, 1H, CO-NH-NH); 7.38 (s, 2H,Ph-OH); 6.78 (s, 1H, OH); 6.60 (m, 2H, Ph-NH2); 5.80 (broad s, 2H, NH2); 1.50 (s,18H, 2 x tBu).21.3) N-[3,5-bis-(l,l-dimethyIethyI)-4-hydroxyphenyl]-N'-{{4-[(2-thienyl(imino)methyl)amino]phenyl}carbonylamino}-ureahydrochloride: 21The experimental protocol used is the same as that described for compound 1, withN-[(4-aminophenyl)carbonylamino]-N'-[3,5-bis-(l, 1 -dimethylethyl)-4-hydroxyphenyl]-urea replacing 3,5-bis-( 1,1 -dimethyl ethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide. The free base is purified on a silica column(eluent: heptane / ethyl acetate: 1 / 1). The pure fractions are collected andconcentrated under reduced pressure. The evaporation residue is diluted in 15 ml ofacetone and salified by a molar solution of HCl in anhydrous ether, as describedpreviously. Finally 0.40 g (58 %) of a yellow powder is obtained. Melting point:254-255 °C.NMR 'H (400 MHz, DMSO, 5): 11.68 (broad s, 1H, NH4); 10.32 (s, 1H, NH amide);9.94 (broad s, 1H, NH+); 9.13 (broad s, 1H, NH4); 8.68 (s, 1H,NH-CO); 8.18 (m, 2H, thiophene); 8.07 (m, 3H, CO-NH-NH + Ph-NH);7.58 (m, 2H, Ph-NH); 7.39 (m, 1H, thiophene); 7.22 (s, 2H, Ph-OH);6.60 (s, 1H, OH); 1.36 (s, 18H, 2 x'tBu).IR: v0h: 3627 cm"1; vc=0 (amide), vc=o (urea): 1654 cm"1,' 1602 cm"1;Vc=n (amidine): 1559cm"1.txample 22: N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-{{4-[(2-thienyl(imino)methyl)amino]phenyl}methyl}-thiourea hydrochloride: 2222.1) N-[3,5-bis-(l,l-dimethylethyI)-4-hydroxyphenyl]-N'-[(4-nitrophenyl)methyl]-thiourea:Compound 22.1 is obtained by the action of Lawesson's reagent on intermediate 17.4according to a experimental protocol described in the literature (J. Med. Chem.(1995), 38 (18), 3558-3565). A light yellow powder is obtained with a yield of80 %. Melting point: 218-220 °C.NMR 'H (100 MHz, CDC13, 5): 7.85 (m, 4H, Ph-NOz); 7.70 (s, 1H, NH-Ph); 7.05 (s,2H, Ph-OH); 6.21 (m, 1H, NH-CH2); 5.40 (s, 1H, OH); 5.00 (d, 2H, CH2, J = 6.5Hz); 1.41 (s, 18H,2xtBu).22.2) N-[(4-aminophenyl)methyl]-N'-[3,5-bis-(l,l-difnethyIethyl)-4-hy droxyp heny I]-thiourea:The experimental protocol used is the same as that described for intermediate 18.2,with intermediate 22.1 replacing 3-[(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyI]-N-(4-hydroxy-3-nitrophenyl)-2-propenamide. A beige powder is obtained with ayield of 70 %. Melting point: 167-169 °C.NMR (100 MHz, CDC13, 8): 7.48 (broad s, 1H, NH-Ph); 6.95 (s, 2H,Ph-OH); 6.81 (m, 4H, Ph-NH2); 5.98 (m, 1H, NH-CH2); 5.28 (s, 1H, OH); 4.69 (d,2H, CH2, J = 5.5 Hz); 3.62 (broad s, 2H, NH2); 1.40 (s, 18H, 2 x tBu).22.3) N-[3,5-bis-(l,l-dimethylethyI)-4-hydroxyphenyI]-N'-{{4-[(2-thienyl(imino)methyl)amino]phenyI}methyl}-thiourea hydrochloride: 22The experimental protocol used is the same as that described for intermediate 17.6,with intermediate 22.2 replacing N-[(4-aminophenyl)methyl]-N'-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-urea. A pale yellow powder is obtained with ayield of 15 %. Melting point: 203-205 °C.NMR *H (400 MHz, DMSO d6, 8): 11.52 (broad s, 1H, NH4); 9.86 (broad s, 1H,NH+); 8.98 (broad s, 1H, NH4); 8.39 (s, 1H, NH-Ph); 8.16 (m, 2H, thiophene); 7.46(m, 6H, Ph-N, thiophene, NH-CH2); 7.18 (s, 2H, Ph); 6.92 (s, 1H, OH); 4.80 (broads, 2H, CH2); 1.35 (s, 18H, 2 x tBu>.IR: Voh'- 3630 cm"1; vc=o (urea): 1649 cm"1' Vc=n (amidine): 1600 cm"1.Exam£le23: N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-{2-{4-[(2-thienyl(imino)methyI)amino]phenyl}ethyl}-urea hydrochloride: 2323.1) N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-[2-(4-nitropheny l)ethyl] -urea:The experimental protocol used is the same as that described for intermediate 21.1,with 4-nitrophenetylamine replacing 4-nitrobenzoyl-hydrazide. A beige powder isobtained with a yield of 80 %. Melting point: 185-187 °C.NMR *H (100 MHz, CDC13,8): 7.75 (m, 4H, Ph-N02); 7.00 (s, 2H, Ph-OH); 6.05 (s,1H, OH); 5.18 (s, 1H, NH); 4.68 (m, 1H, NH-CH2); 3.50 (m, 2H,NH-CHi); 2.92 (m, 2H, CH2); 1.40 (s, 18H, 2 x tBu).23.2) N-[2-(4-aminophenyl)ethyl]-N'-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-urea:The experimental protocol used is the same as that described for intermediate 21.2,with intermediate 23.1 replacing N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-[(4-nitrophenyl)-carbonylamino]-urea . A white powder is obtained with a yieldof 56%. Melting point: 192-194 °C.NMR (100 MHz, DMSO d6,8): 8.25 (broad s, 1H, Ph-NH-CO); 7.22 (s, 2H, Ph-OH); 6.79 (m, 4H, Ph-NH2); 6.65 (s, 1H, OH); 5.92 (m, 1H, NH-CH2); 4.98 (broads, 2H, -NH2); 3.31 (m, 2H, NH-GH?); 2.65 (m, 2H, CH2); 1.48 (s, 18H, 2 x-tBu).23.3) N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-N'-{2-{4-[(2-thienyI(imino)methyl)aminojphenyl}ethyl}-urea hydrochloride: 23The experimental protocol used is the same as that described for compound 1, withintermediate 23.2 replacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide. The free base is purified on a silica column (eluent:heptane / ethyl acetate: 1 / 1). The pure fractions are collected and concentrated underreduced pressure. The evaporation residue is diluted in 15 ml of acetone and salifiedby a molar solution of HC1 in anhydrous ether, as described previously. Finally 0.25g (24 %) of a pale yellow powder is obtained. Melting point: 207-210 °C.NMR 'H (400 MHz, DMSO d6, 8): 11.48 (broad s, 1H, NH4); 9.83 (broad s, 1H,NH4); 8.95 (broad s, 1H, NH4); 8.50 (s, 1H, NH-CO); 8.18 (m, 2H, thiophene); 7.38(m, 5H, Ph-NH + thiophene); 7.18 (s, 2H, Ph-OH);6.55 (s, 1H, OH); 6.21 (m, *1H, CO-NH-CH2); 3.35 (m, 2H, NH-CH?);2.78 (m, 2H, CH2); 1.36 (s, 18H, 2 x tBu).IR: v0h: 3631 cm"1; vc=o (urea): 1654 cm"1, 1600 cm"1; vc=n (amidine): 1560 cm"1.txample 24: N-(4-{4- [(3,4-dihydro-6-methoxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonyl]-l-piperazinyl}phenyI)-2-thiophenecarboximidamidehydrochloride: 2424.1) l-{[3,4-dihydro-6-methoxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl]carbonyI}-4-(4-nitrophenyl)piperazine:The experimental protocol is identical to that described for intermediate 13.1, with(±)-3,4-dihydro-6-methoxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-carboxylicacid(prepared according to CHI MA (1991), 45 (4), 121-3) replacing (±)-Trolox®. Ayellow powder is obtained.NMR *H (100MHz, CDC13, 8): 7.45 (m, 4H, Ph); 3.60 (s, 3H, CH30);3.40 (m, 4H, piperazine); 3.00 (m, 4H, piperazine); 2.50-1.60 (m, 16H, Trolox®).24.2) l-{(3,4-dihydro-6-methoxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl]carbonyl}-4-(4-aminophenyl)piperazine:The experimental protocol is identical to that described for intermediate 13.2, withintermediate 24.1 replacing 3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-nitrophenyl)-l-piperazinyl]-carbonyl}-2H-l-benzopyran-6-ol. An oil is obtained which is useddirectly in the following stage.NMR 'H (100MHz, CDC13, 5): 6.70 (m, 4H, Ph); 3.90 (broad d, 4H, piperazine);3.60 (s, 3H, ch3o); 3.45 (broad s, 2H, NH2); 2.90 (m, 4H, piperazine);2.60-1.60 (m, 18H, Trolox®).24.3) N-(4-{4- [(3,4-dihydro-6-methoxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonyl]-l-piperazinyl}phenyl)-2-thiophenecarboximidamidehydrochloride: 24The experimental protocol is the same as that described for compound .13, withintermediate 24.2 replacing 3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-aminophenyI)-l-piperazinyl]-carbonyl}-2H-l-benzopyran-6-ol. A pale yellow powder is obtained..Melting point: 190-195 °C.NMR *H (400MHz, DMSO, 5): 11.35 (broad s, 1H, NH+); 9.70 (broad s, 1H, NH+);8.70 (broad s, 1H, NH4); 8.15 (broad s, 2H, thiophene); 7.35 (broad s, 1H,thiophene); 7.17 (m, 4H, Ph); 3.90 (broad d, 4H, piperazine); 3.50 (s, 3H, ch3o);3.15 (m, 4H, piperazine); 2.55-1.55 (m, 16H, Trolox®).IR: voo (amide): 1642 cm'l; vc=N (amidine): 1618 cm"1.9Example 25: N-[4-{4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonyI]-lH-l,4-diazepin-l-yl}phenyl]-2-thiophenecarboximidamide hydrochloride: 2525.1) hexahydro-4-(4-nitrophenyl)-lH-l,4-diazepine:3.37 g (24.4 mmoles) of potassium carbonate and 1.89 g (13.4 mmoles) of 4-nitrofluorobenzene are added to a solution of 2.44 g (12.2 mmoles) of (1,1-dimethyl)ethyl hexahydro-1H-1,4-diazepine-1 -carboxylate in 50 ml of DMF. The reactionmixture is heated at 100 °C for 16 hours. After cooling down, 25 ml of ethyl acetateand 50 ml of water are added. The organic solution is decanted and the aqueousphase extracted with 3 times 50 ml of ethyl acetate. The organic phases arecombined and washed with 50 ml of salt water, dried over sodium sulphate, filteredand concentrated under vacuum. 3.7g of a bright yellow solid is obtained with ayield of 95 %. This solid is then dissolved in 100 ml of a mixture of solvents(dichloromethane / ethyl acetate 1:1) to which 20 ml of an aqueous solution (6N) ofhydrochloric acid is added dropwise, at 0 °C. After vigorous stirring, at 20 °C, for 1hour, the reaction mixture is decanted. The aqueous phase is rendered basic topH = 11 using 4N soda and extracted with 3 times 50 ml of dichloromethane. Theorganic phases are combined, washed with 50 ml of water followed by 50 ml of saltwater, dried over sodium sulphate and finally filtered and concentrated undervacuum. 1.78 g of a bright yellow powder is obtained with a yield of 66 %. Theproduct is used directly in the following stage without additional purification.NMR 'H (100MHz, cdci3, 5): 8.10 (m, 2H, Ph); 6.65 (m, 2H, Ph);3.70 (q, 4H, CH2N, j = 5.2 Hz); 3.10 (t, 2H, CH2N); 2.85 (t, 2H, CH2N);1.95 (q, 2H, C-CH2-C); 1.65 (broad s, 1H NH).25.2) l-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyI-2H-l-benzopyran-2-yl)carbonyI] hexahydro-4-(4-nitrophenyl)-lH-l,4-diazepine:0.71 g (4.4 mmoles) of 1.l'-carbonyldiimidazole is added to a solution of 1.07 g (4.3mmoles) of (±)-Trolox® in 8 ml of anhydrous THF in a 50 ml flask. After stirringfor one hour at 20 °C a solution of 0.95 g (4.3 mmoles) of intermediate 25.1 in 4 mlof DMF is added dropwise. The reaction mixture is stirred for 16 hours at 20 °C.After evaporation of the solvents under vacuum, the residue is taken up in 30 ml of amixture of solvents (dichloromethane / water 1:2). After decantation,r the organicphase is washed twice with 20 ml of water, dried over sodium sulphate andconcentrated under vacuum. A pale yellow powder is obtained with a crude yield of97 %. The product is used directly in the following stage without additional,purification.NMR 'h (IOOMHz, cdci3, 5): 8.10 (m, 2H, Ph); 6.60 (m, 2H, Ph); 4.40 (broad s;1H, OH); 3.50 (m, 8H, CH2N); 2.50-1.50 (m, 18H, Trolox® + CH2).25.3) l-(4-aminophenyl)-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonyI] hexahydro-lH-l,4-diazepine:The experimental protocol used is the same as that described for intermediate 13.2,with intermediate 25.2 replacing 3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-nitrophenyl)-l-piperazinyl]-carbonyl}-2H-l-benzopyran-6-ol. The reaction productis purified on a column of silica gel (eluent: ethyl acetate / petroleum ether 3:2). Anoil is obtained with a yield of 57 %.25.4) N-[4-{4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yI)carbonyl]-lH-l,4-diazepin-l-yl}phenyl]-2-thiophenecarboximidamidehydrochloride:A mixture of 0.52 g (1.22 mmole) of intermediate 25.3 and 0.35 g (1.22 mmole) ofS-methyl-2-thiophene thiocarboximide hydroiodide in 4 ml of isopropanol is heatedat 50 °C for 40 hours. The reaction mixture is then filtered and the solid obtained istaken up in 4 ml of a saturated aqueous solution of sodium carbonate and 4 ml ofethyl acetate. The mixture is heated at 50 °C for 30 minutes, then decanted. Theorganic phase is washed twice with 10 ml of water followed by 10 ml of salt water.The organic phases are combined, dried over sodium sulphate, filtered andconcentrated under reduced pressure. The solid obtained is purified on a column ofsilica gel (eluent: ethyl acetate / petroleum ether 5:1). 0.5 g of product is obtainedwith a yield of 77 %. 0.15 g (0.29 mmole) of this product are then dissolved in 2 mlof acetone. 0.84 ml (0.84 mmole) of a IN solution of hydrochloric acid inanhydrous ethyl ether is added dropwise. The mixture is stirred at ambienttemperature for 30 minutes. A yellow precipitate forms which is filtered. Theprecipitate is triturated and washed successively with 3 times 5 ml of ethyl ether and5 ml of acetone. The dark yellow powder is dried under vacuum at 70 °C for 48hours. The yield obtained is 80 %. Melting point: 180-185 °C.NMR *H (400MHz, DMSO, 8): 11.15 (broad s, 1H, NH4); 9.60 (broad s, 1H, NH4);8.55 (broad s, 1H, NH4); 8.10 (broad s, 2H, thiophene); 7.35 (broad s, 1H,thiophene); 7.02 (m, 4H, Ph); 4.80 (broad s, 1H, OH); 3.70 (m, 8H, CH2N); 2.50-1.40 (m, 18H, Trolox® + CH2).IR: V0h: 3412 cm'1; Vc=o (amide): 1613 cm"1; VC=N (amidine): 1613 cm"1.Example 26: (R)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)-carbonyl]-l-piperazinylIphenyl}-2-thiophenecarboximidamide hydrochloride: 2626.1) ( / ?)-3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-nitrophenyl)-l-piperazinyl]-carbonyl}-2H-l-benzopyran-6-ol:The experimental protocol used is the same as that described for compound 13.1,with (7?;-Trolox® replacing (±)Trolox®. A bright yellow powder is obtained with ayield of 98%. Melting point: 102-105 °C.26.2) ( / ?)-3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-aminophenyl)-l-piperazinyl]-carbonyI}-2H-l-benzopyran-6-ol:The experimental protocol used is the same as that described for Intermediate 2.2,with intermediate 26.1 replacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[(4-nitrophenyl)methyl]-benzamide. A pink powder is obtained with a yield of 75%.The product is used as it is in the following stage. Melting point: 103-105 °C.26.3) (R)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyI-2H-l-benzopyran-2-yl)-carbonyl]-l-piperazinyl]phenyl}-2-thiophenecarboximidamide hydrochloride: 26The experimental protocol used is the same as that described for compound 13, withintermediate 26.2 replacing 3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-aminophenyl.)-l-piperazinyl]-carbonyl}-2H-l-benzopyran-6-ol. The product is obtained in theform of a pale yellow powder which hydrates in air. Melting point: 195-197 °C.The NMR and IR analyses are identical to compound 13.[a]*°=-43.5° (c=o.11 ; DMSO)Example 27: (S)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)-carbonyl]-l-piperazinyl]phenyl}-2-thiophenecarboximidamide dihydrochloride: 2727.1) (S)-3,4-dihydro-2,5,7,8-tetramethyl-2-{4-f(4-nitrophenyl)-l-piperazinyl]-carbonyl}-2H-l-benzopyran-6-ol:The experimental protocol used is the same as that described for compound 13.1,with (S^-Trolox® replacing (±)Trolox®. A yellow powder is obtained with a yieldof 73%. Melting point: 110-111 °C.27.2) (5r)-3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-aminophenyl)-l-piperazinyl|-carbonyl}-2H-l-benzopyran-6-ol:The experimental protocol used is the same as that described for Intermediate 2.2,with intermediate 27.1 replacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[(4-nitrophenyl)methyl]-benzamide. After purification on a column of silica gel(heptane / ethyl acetate: 2 / 8), collection and evaporation under vacuum of the purefractions, a beige powder is obtained with a yield of 54%. Melting point: 109-111 °C.27.3) (S)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)-carbonyl]-l-piperazinyl]phenyl}-2-thiophenecarboximidamide dihydrochloride: 27The experimental protocol used is the same as that described for compound 13, withintermediate 27.2 replacing 3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-aminophenyl)-l-piperazinyl]-carbonyl}-2H-l-benzopyran-6-ol. The product is obtained in theform of a pale yellow powder which hydrates in air. Melting point: 210.6-211.8 °C.The NMR and IR analyses are identical to compound 13.[a] 2d°=+76.2° (c=0.17 ; DMSO)Alternatively compound 27 can be prepared according to the following protocol:27.4) methyl 2 -thiophene carboximidate:i10.91 g (0.1 mole) of 2-thiophene carbonitrile, 100 ml of anhydrous ethyl ether and4.5 ml (0.11 mole) of methanol are introduced into a 250 ml Erlenmeyer flaskpurged with argon. The solution is cooled down to 0 °C, using an ice bath, andsaturated with a stream of anhydrous HC1 gas for 45 minutes. The reaction mixtureis stirred for another hour at 0 °C and overnight at 20 °C. The precipitate formed isfiltered, washed with ethyl ether and dried. The hydrochloride obtained ispartitioned in a mixture of 100 ml of water and 150 ml of ethyl ether. The mediumis neutralized by adding 8.4 g (0.1 mole) of dry NaHC03. After decantation andseparation, the organic phase is washed successively with 2 x 30 ml of water and 30ml of salt water. After drying over sulphate of magnesium, the organic solution isfiltered and concentrated under vacuum. A colourless oil is obtained with a yield of66 %.NMR 'H (400 MHz, CDC13, 5): 7.58 (broad s, 1H, =N-H); 7.42 (m, 1H, thiophene);7.37 (m, 1H, thiophene); 7.01 (m, 1H, thiophene); 3.86 (s, 3H, OCH3).IR: vc=N (carboximidate): 1630 cm"1.27.5) (S)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)-carbonyl]-l-piperazinyllphenyl}-2-thiophenecarboximidamide dihydrochloride: 278.2g (20 mmoles) of (S>3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-aminophenyl)-l-piperazinyl]-carbonyl}-2H-l-benzopyran-6-ol (obtained as intermediate 13.2 butstarting from (S)-Trolox®) is dissolved in 60 ml of methanol in a 150 ml Erlenmeyerflask, under a stream of argon and 4.2 g (30 mmoles) of methyl 2-thiophenecarboximidate is added. The reaction mixture is heated for 18 hours under reflux.The methanol is evaporated off under vacuum and the brown oily residue is purifiedon a column of silica gel (eluent: dichloromethane / ethanol: 95 / 5). The pure fractionsare collected and concentrated under vacuum in order to produce a brown oil with ayield of 68 %. This oil is taken up in 22 ml of an ethanolic solution of HC1 (1.3N)and diluted with 180 ml of anhydrous acetone. The reaction mixture is stirred for 1hour at 0 °C. The precipitate formed is filtered and washed successively withacetone and with ethyl ether. After drying, the dihydrochloride is obtained in the.form of a pale yellow powder with a yield of 53 %.Example 28: 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{2-[3-[(2-thienyl(imino)methyl)amino]phenyl]ethyl}-benzamide hydrochloride: 2828.1) 3,5-bis-(l,l-dimethylethyI)-4-hydroxy-N-[2-(3-nitrophenyI)ethyI]-benzamide:The experimental protocol used is the same as that described for intermediate 5.1,with 3-nitrophenetylamine (J. Med. Chem. (1968), 11 (1), 21-26) replacing 4-nitrophenetylamine. A white powder is obtained with a yield of 50 %. Meltingpoint: 195-197 °C.NMR 'H (100 MHz, cdci3, 5): 7.86 (m, 4H, Ph-N02); 7.50 (s, 2H, Ph); 6.10 (m,1H, NHCO); 5.54 (s, 1H, OH); 3.75 (m, 2H, CH2-NHCO);3.08 (m, 2H, CH?-Ph-NO->): 1.42 (s, 18H, 2 x tBu).28.2) 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(2-(3-aminophenyl)ethyl]-benzamide:The experimental protocol used is the same as that described for intermediate 5.2,with intermediate 28.1 replacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[2-(4-nitrophenyl)ethyl]-benzamide. A white powder is obtained (yield of 40 %) which issufficiently pure to be used directly in the following stage.28.3) 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{2-[3-[(2-thienyI(imino)methyl)-amino]phenyI]ethyl}-benzamide hydrochloride: 28_The experimental protocol used is the same as that described for intermediate 1.3,with intermediate 28.2 replacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide. A pale yellow powder is obtained with a yield of 35 %.Melting point: 205-207 °C.NMR 'H (400 MHz, DMSO d6, 8): 11.59 (broad s, 1H, NH4); 9.89 (s, 1H, NH4);8.95 (s, 1H, NH4); 8.46 (s, 1H, CONH); 8.17 (m, 2H, thiophene); 7.54 (s, 2H, Ph-OH); 7.39 (m, 6H, thiophene, Ph-NH, OH); 3.51 (m, 2H, CH,-NHCO);2.89 (m, 2H, CH,-Ph-NH): 1.38 (s, 18H, 2 x tBu).IR: v0H: 3624 cmf1; Vc=0 (amide): 1631 cm"1' VC=N (amidine): 1577 cm"1.Example 29: N-{4-(4-[2-(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl)-l-oxo-ethyl]-l-piperazinyl)phenyI}-2-thiophenecarboximidamide hydrochloride: 29The experimental protocol used is the same as that described for compound 9, with3,5-di-ter / -butyl-4-hydroxyphenylacetic acid replacing 3,5-di-tert-butyl-4-hydroxybenzoic acid in the first stage of synthesis. Yellow powder. Melting point:176-180 °C.NMR *H (400 MHz, DMSO d6, 5): 11.30 (broad s, 1H, NH4); 9.70 (broad s, 1H,NH4); 8.65 (broad s, 1H, NH4); 8.10 (broad s, 2H, thiophene); 7.35 (broad s, 1H,thiophene); 7.12 (m, 4H, Ph-N); 6.95 (s, 2H, Ph-OH); 6.80 (broad s, 1H, OH); 3.60(broad s, 6H, piperazine, CH2CO); 3.10 (m, 4H, piperazine); 1.35 (s, 18H,2x tBu).IR: v0H: 3620 cm"'1 Vc=o (ester): 1638 cm"1' VC=N (amidine): 1612 cm"1.Example 30: 2-{4-[(2-thienyl(imino)methyl)amino]phenyI}ethyI 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-benzoate hydrochloride: 3030.1) 2-(4-nitrophenyl)ethyl 3,5-bis-(l,l-dimethylethyl)-4-hydroxybenzoate:2.45 g (9.8 mmoles) of 3,5-di-ter / -butyl-4-hydroxybenzoic acid, 1.8 g (10.8 mmoles)of 4-nitrobenzene-ethanol and 2.2 g (10.8 mmoles) of dicyclohexylcarbodiimide areintroduced successively, under stirring, into a 250 ml flask containing 80 ml of THF,under an argon atmosphere. The reaction mixture is stirred for 15 hours at 20 °C andthe precipitate which appears is filtered. The filtrate is washed with 2 x 30 ml of asaturated solution of NaCl, the organic phase is dried over sulphate of magnesium,filtered and concentrated under vacuum. The residue is then crystallized using di-isopropyl ether. The solid is recovered by filtration and 2.4 g (62%) of whitecrystals is obtained after drying. Melting point: 123.5-124.5 °C.NMR *H (100 MHz, cdci3, 5): 7.85 (m, 4H, Ph-N02); 7.80 (s, 2H, Ph-OH); 5.70 (s,1H, OH); 4.50 (m, 2H, 0-CH2); 3.20 (m, 2H, CH2); 1.40 (s , 18H, 2x tBu).30.2) 2-(4-aminophenyI)ethyI 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-benzoate:The experimental protocol is the same as that described for intermediate 2.2, withintermediate 30.1 replacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-[(4-nitrophenyl)-methyl]-benzamide. A white powder is obtained with a yield of 50 %.Melting point: 135-136 °C.NMR 'H (400 MHz, DMSO d6, 5): 7.75 (s, 2H, Ph-OH); 6.70 (m, 4H, Ph-N); 4.90(broad s, 1H, OH); 4.25 (m, 2H, 0-CH2); 3.30 (broad s, 2H, NH2);2.80 (m, 2H, CH2); 1.40 (s, 18H, 2 x tBu).30.3) 2-{4-[(2-thienyl(imino)methyl)amino]phenyl}ethyl 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-benzoate hydrochloride: 30The experimental protocol is the same as that described for intermediate 1.3, withintermediate 30.2 replacing 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4-aminophenyl)-benzamide. A white solid is obtained with a yield of 26%. Meltingpoint: 145-150 °C.NMR !H (400 MHz, DMSO d6, 8): 11.50 (broad s, 1H, NH4); 9.80 (broad s, 1H,NH4); 8.90 (broad s, 1H, NH4); 8.20 (broad s, 2H, thiophene); 7.85 (s, 1H, OH);7-75 (s, 2H, Ph-OH); 7.47 (m, 5H, Ph-N, thiophene); 4.41 (m, 2H,0-CH2); 3.08 (m, 2H, CH2);1.40 (s, 18H, 2 x tBu).IR: vc=o (ester): 1700 cm"1: vc=N (amidine): 1592 cm"1.Example 31: 2-{3-f(2-thienyI(imino)methyl)aminolphenyI}ethyI 3,5-bis-(l,l-dimethyIethyI)-4-hydroxy-benzoate hydrochloride: 31The experimental protocol used is the same as that described for compound 30, with3-nitrobenzene-ethanol replacing 4-nitrobenzene-ethanol in the first stage ofsynthesis. Pale yellow powder. Melting point: 145-148 °C.NMR JH (400 MHz, DMSO d6, 5): 11.50 (broad s, 1H, NH4); 9.82 (broad s, 1H,NH4); 8.99 (broad s, 1H, NH4); 8.15 (m, 2H, thiophene); 7.81 (s, 1H, OH); 7.75 (s,2H, Ph-OH); 7.41 (m, 5H, Ph-N, thiophene); 4.41 (m, 2H, 0-CH2); 3.08 (m, 2H,CH2); 1.38 (s, 18H, 2 x tBu).ir: v0h: 3620 cm~1; vc=o (ester): 1707 cm"1; vc=n (amidine): 1654 cm"1.Example 32: 2-{2-[(2-thienyI(imino)methyl)amino]phenyl}ethyl 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-benzoate hydrochloride: 32The experimental protocol used is the same as that described for compound 30, with2-nitrobenzene-ethanol replacing 4-nitrobenzene-ethanol in the first stage ofsynthesis. Powder beige. Melting point: 139-145 °C.NMR (400 MHz, DMSO d6, 5): 11.50 (broad s, 1H, NH4); 9.80 (broad s, 1H,NH4); 8.65 (broad s, 1H, NH4); 8.15 (m, 2H, thiophene); 7.80 (s, 1H, OH); 7.70 (s,2H, Ph-OH); 7.60 (m, 1H, Ph); 7.45 (m, 3H, Ph); 7.35 (s, 1H, thiophene); 4.40 (m,2H, 0-CH2); 3.00 (m, 2H, CH2); 1.-35 (s, 18H, 2 x tBu).IR: vc=o (ester): 1728 cm"1; VC=n (amidine): 1649 cm"1.Pharmacological studv of the products of the inventionStudy of the effects on neuronal constitutive NO synthase of a rat's cerebellumThe inhibitory activity of the products of the invention is determined by measuringtheir effects on the conversion by NO synthase of [ H]L-arginine to [ H]L-citrulhneaccording to the modified method of Bredt and Snyder (Proc. Natl. Acad Sci. USA,(1990) 87: 682-685). The cerebellums of Sprague-Dawley rats (300g - CharlesRiver) are rapidly removed, dissected at 4°C and homogenized in a volume ofextraction buffer (50 mM HEPES, 1 raM EDTA, pH 7.4, pepstatin A 10 mg / ml,leupeptin 10 mg / ml). The homogenates are then centrifuged at 21000 g for 15minutes at 4°C. Dosage is carried out in glass test tubes in which 100 fxl ofincubation buffer containing 100 mM of HEPES (pH 7.4), 2 mM of EDTA, 2.5 mMof CaCl2, 2 mM of dithiotreitol, 2 mM of reduced NADPH and 10 (ig / ml ofcalmodulin are distributed. 25 |il of a solution containing 100 nM of [3H]L-arginine(Specific activity: 56.4 Ci / mmole, Amersham) and 40 fiM of non-radioactive L-arginine is added. The reaction is initiated by adding 50 of homogenate, the finalvolume being 200 (the missing 25 fxl are either water or the tested product). After15 minutes, the reaction is stopped with 2 ml of stopping buffer (20 mM of HEPES,pH 5.5, 2 mM of EDTA). After passing the samples through a 1 ml column ofDOWEX resin, the radioactivity i§ quantified by a liquid scintillation spectrometer.The compounds of the examples 6, 7, 13 and 14 described above show an ic50 lowerthan 3.5 p.M.Study of the effects on lipidic peroxidation of the cerebral cortex of a ratThe inhibitory activity of the products of the invention is determined by measuringtheir effects on the degree of lipidic peroxidation, determined by the concentration ofmalondialdehyde (MDA). The MDA produced by peroxidation of unsaturated fattyacids is a good indication of lipidic peroxidation (H Esterbauer and KH Cheeseman,Meth. Enzymol. (1990) 186: 407-421). Male Sprague Dawley rats of 200 to 250 g(Charles River) were sacrificed by decapitation. The cerebral cortex is removed, then,homogenized using a Thomas potter in a 20 mM Tris-HCl buffer, pH = 7.4. Thehomogenate was centrifuged twice at 50000 g for 10 minutes at 4°C. The pellet isstored at -80°C. On the day of the experiment, the pellet is replaced in suspension ata concentration of 1 g / 15 ml and centrifuged at 515 g for 10 minutes at 4°C. Thesupernatant is used immediately to determine the lipidic peroxidation. Thehomogenate of rat's cerebral cortex (500 jxl) is incubated at 37°C for 15 minutes inthe presence of the compounds to be tested or of solvent (10 fil). The lipidicperoxidation reaction is initiated by adding 50 |nl of 1 mJVI FeCb, 1 mM EDTA and4 mM ascorbic acid. After incubation for 30 minutes at 37°C, the reaction is stoppedby adding 50 p. 1 of a solution of hydroxylated di tertio butyl toluene (BHT, 0.2 %).The MDA is quantified using a colorimetric test, by reacting a chromogenic reagent(R), N-methyl-2-phenylindol (650 |il) with 200 (il of the homogenate for 1 hour at45°C. The condensation of one MDA molecule with two molecules of reagent Rproduces a stable chromophore the maximum absorbence wavelength of which isequal to 586 nm. (Caldwell et al. European J. Pharmacol. (1995) 285, 203-206). Thecompounds of the examples 5, 8, 9, 10, 12, 13, 14, 16, 17, 18, 19, 20, 21, 26 and 27described above all show an IC50 lower than 30 |iM.

Claims

CLAIMS 1. Product characterized in that it corresponds to the general formula (I) in which: A represents: either a radical in which Rj and R2 represent, independently, a hydrogen atom, a halogen, the OH group, a linear or branched alkyl or alkoxy radical with 1 to 6 carbon atoms, R3 represents a hydrogen atom, a linear or branched alkyl radical with 1 to 6 carbon atoms or a -COR4 radical, R4 representing a linear or branched alkyl radical with 1 to 6 carbon atoms, or a radical in which R3 has the meaning indicated above or a H radical in which R5 represents a hydrogen atom, the OH group or a linear or branched alkyl or alkoxy radical with 1 to 6 carbon atoms; B represents a linear or branched alkyl radical with 1 to 6 carbon atoms, carbocyclic or heterocyclic aryl radical with 5 or 6 members containing 1 to 4 heteroatoms chosen from O, S, N and in particular the thiophene, furane, pyrrole or thiazole radicals, the aryl radical being optionally substituted by one or more groups chosen from the linear or branched alkyl, alkenyl or alkoxy radicals with 1 to 6 carbon atoms; X represents -Zr, -Zi-CO-, -CH=CH-CO-, -Z1-NR3-CO-, -Z1-NR3-CS-, -Z1-NR3-SO7- or a single bond; Y represents a radical chosen from the -Z2-Q, piperazine, homopiperazine,2-methylpiperazine, 2,5-dimethylpiperazine, 4-aminopiperidine, -NR3-Z2-Q-> -NR3-CO-Z2-Q-, -NR3-NH-CO-Z2-, -nh-nh-z2-, -nr3-o-z2-, -NR3-SO2-NR3-Z2-, -O-Z2-Q-, -O-CO-Z2-Q- or -S-Z2-Q- radicals, in which Q represents a single bond, 0-Z3, R3-N-Z3 or S-Z3; » Zi, Z2 and Z3 represent independently a single bond or a linear or branched alkylene radical with 1 to 6 carbon atoms, Zi, Z2 and Z3 preferably representing -(CH2)m-, m being an integer from 0 and 6; Rg represents a hydrogen atom or an OH group; or a salt of a product of general formula (I), - 74with the exception however of the compound of the following formula:

2. Product according to claim 1, characterized in that it is one of the following compounds: - 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{4-[(2-thienyl (imino)methyl)amino]phenyl}-benzamide; - 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N-{4-[[(2-thienyl (imino)methyl)amino]phenyl]methyl}-benzamide; - 4-acetoxy-3,5-dimethoxy-N-{4-[[(2-thienyl(imino)methyl)amino]phenyl]methyl}benzamide; - 3,5-dimethoxy-4-hydroxy-N-{4-[[(2-thienyl(imino)methyl)amino]phenyl]methyl}benzamide; - 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{4-[2-[(2-thienyl(imino)methyl)amino]phenyl]ethyl}-benzamide; » - 4-acetoxy-3,5-dimethoxy-N-{4-[2-[(2-thienyl-(iinino)methyl)amino]phenyl]ethyl}-benzamide; - 3,5-dimethoxy-4-hydroxy-N-{4-[2-[(2-thienyl-(imino)methyl)amino]pheny 1 ]e thy 1} -benzamide; - 3,4,5-trihydroxy-N-{4-[2-[(2-thienyl(imino)methyl)-amino]phenyl]ethyl}benzamide; - N- [4-[4-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxybenzoyl]-1 -piperazinyl]-phenyl} 2-thiophenecarboximidamide; - N- {4-[4-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxybenzyl]- l-piperazinyl]phenyl} 2-thiophenecarboximidamide; - N-{4-[4-[3,5-dimethoxy-4-hydroxybenzoyl]-l-piperazinyl]-phenyl}2-thiophenecarboximidamide; - 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-{4-[(2-thienyl (imino)methyl)amino]phenyl}-2H-l-benzopyran-2-carboxamide; -75. N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyI-2H-l-benzopyran-2-y!)carbonyl]-1 -piperaziny I ]phe ny 1} -2-thiophenecarboximidamide; . N-{4-[4-[(5-methoxy-lH-indol-3-yl)methylcarbonyl]-l-piperazinyIJphenyl}2-thiophenecarboximidamide; . N-[4-[4-[{3-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]-l-oxo-2-propenyl}1- piperazinyl]-phenyl]]-2-thiophenecarboximidamide; - 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{3-[[(2-thienyl(imino)methyl)amino]phenyl]methyl}-benzamide; - N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]N’-{{4-[(2-thienyl(imino)methyl)amino]phenyl} methyl}-urea; - N-[5-[{3-(3,5-bis-( 1,1 -dimethylethyl)-4-hydroxypheny 1)-l-oxo-2propenyl}amino]-2-hydroxyphenyl]-2-thiophenecarboximidamide; - N-[3-[{3-(3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl)-1 -oxo-2-propeny 1}amino]-4-hydroxyphenyl]-2-thiophenecarboximidamide; - N-{4-[4-[3,4,5-trihydroxybenzoyl]-l-piperazinyl]phenyl}2- thiophenecarboximidamide; - N-[3,5-bis-( 1,1-dimethy lethy l)-4-hydroxyphenyl]N’ - {{4- [(2-th ie ny l(imino)methyl)amino]phenyl} carbony lamino} -urea; - N-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenyl]N’-{{4-[(2-thienyl(imino)methyl)amino]phenyl} methyl}-thiourea; - N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl]N’-{2-{4-[(2-thienyl(imino)methyl)amino]phenyl} ethyl} -urea; - N-(4- {4- [(3,4-dihydro-6-methoxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl) carbonyl]-l-piperazinyl}pheny 1)-2-thiophenecarboximidamide; - N-[4-{4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl) carbonyl]-1 Η-1,4-diazepin-1 -y 1} pheny l]-2-thiophenecarboximidainide; - (R)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonyl]-l-piperazinyl]phenyl}-2-thi0phenecarboximidamide; - (S)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonyl]-l-piperazinyl]phenyl}-2-thiophenecarboximidamide; - 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{2-[3-[(2-thienyl(imino)methyl)amino] phenyljethyl {-benzamide; - N-{4-(4-[2-(3,5-bis-(l,l-dimethylethy!)-4-hydroxyphenyl)-l-oxo-ethyl]1-piperaziny l)phenyl} -2-thiophenecarboximidamide; - 2-{4-[(2-thienyl(imino)methyl)amino]phenyl}ethyl 3,5-bis-(l, l-dimethylethyl)-4hydroxy-benzoate; - 2- {3-[(2-thienyl(imino)methyl)amino]phenyl}ethyl 3,5-bis-( 1,1 -dimethylethy 1)-4hydroxy-benzoate; -76- 2-{2-[(2-thienyl(imino)methyl)amino]phenyl}ethyl 3,5-bis-(l,l-dimethylethyl)-4hydroxy-benzoate; or one of the salts of one of the latter, in particular a hydrochloride, dihydrochloride, fumarate or hemi-fumarate of one of the latter.

3. Product according to claim 1, characterized in that: - X represents a linear or branched alkylene radical with 1 to 6 carbon atoms and Y represents a piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, 4-aminopiperidine, -NR3-Z2-Q-, -NR3-NH-CO-Z2-, -NH-NH-Z2- or -NR3-O-Z2- radical; or -X represents -Ζι-CO- or -CH=CH-CO- and Y represents a piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, 4-aminopiperidine, -NR3-Z2-Q-, -NR3-NH-CO-Z2-, -NH-NH-Z2-, -NR3-O-Z2-, -O-Z2-Q- or -NR3-CO-Q'- radical with Q' = R3-N-Z3; or - X represents -Zi-NR3-CO- and Y represents -Z2-Q-, -NH-Z2-Q-, -NH-CO-Z2-Qwith Q = O-Z3-, R3-N-Z3- or S-Z3-, or Y represents -NR3-SO2-NR3-Z2- or -O-Z2-Q-; or - X represents -Zi-NH-CO- and Y represents a piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, 4-aminopiperidine, -NR3-Z2-Q-, -NR3-NH-CO-Z2-, -NH-NH-Z2- or -NR3-O-Z2- radical; or - X represents -Zi-NR3-SO2- and Y represents -Z2-Q- with Q = O-Z3-, R3-N-Z3- or S-Z3-, or Y represents -NR3-Z2-Q-; or - X represents -Zi- and Y represents -O-CO-Z2-Q-; or -X represents -Zi-NR3-CS- and Y represents -NH-Z2-Q-, or a piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethyl-piperazine, 4-aminopiperidine, -NR3-Z2-Q-, -NH-NH-Z2- or -NR3-O-Z2- radical; or - X represents a bond and Y represents -O-Z2-NH-, -S-Z2-NH-.

4. Product according to claim 1, 2 or 3, characterized in that: - X represents -CO- or -NH-CO-; - and Y represents an -NH-Z2-Q- or piperazine radical, Q representing a bond, O-Z3, R3-N-Z3 or S-Z3, and Z2 and Z3 representing independently a bond or a linear or branched alkylene radical with 1 to 6 carbon atoms and R3 represents a hydrogen atom or a linear or branched alkyl radical with 1 to 6 carbon atoms.

5. Product according to claim 1 or 2, characterized in that it is one of the following compounds: - 3,5-bis-( 1,1 -dimethylethyl)-4-hydroxy-N- {4-[2-[2-thienyl(iminomethy l)amino]phenyl]ethyl} -benzamide; - 3,4,5-trihydroxy-N-{4-[2-[2-thienyl(iminomethyl)-amino]phenyl]ethyl}benzamide; - N-{4-[4-[3,5-bis-(l,l-dimethylethyl)-4-hydroxybenzoyl]-l-piperazinyl]phenyl}-2thiophenecarboximidamide; - N-{4-[4-[3,5-bis-(l,l-dimethylethyl)-4-hydroxybenzyl]-l-piperazinyl]phenyl}-2thiophenecarboximidamide; - 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-{4-[2- thienyl (iminomethyl)amino]phenyl} -2H-1 -benzopyran-2-carboxamide; - N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonyl]-1-piperazinyljphenyl}-2-thiophenecarboximidamide; - N-{4-[4-[(5 methoxy-lH-indol-3-yl)methylcarbonyl]-l-piperazinyl]phenyl}2-thiophenecarboximidamide; - 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-{3-[[2-thienyl(iminomethyl)amino]phenyl]methyl}-benzamide; - N-[3,5-bis-(l,l-dimethylethyl)-4-hydroxypheny 1]-N’{{4-[2~thienyl(iminomethyl)amino]phenyl} methyl} -urea; - N- [5 - [ {3-(3,5-b is-( 1,1 -dimethylethyl)-4-hydroxyphenyl)-1 -oxo-2 -propeny 1} amino]-2-hydroxyphenyl]-2-thiophenecarboximidamide; -78- N-[3-[{3-(3,5-bis-(l,l-dimethylethyl)-4-hydroxyphenyl)-l-oxo-2-propenyl}amino]-4-hydroxyphenylJ-2-thiophenecarboximidamide; _ N-{4-[4-[3,4,5-trihydroxybenzoyl]-l-piperazinyl]phenyl}2-thiophenecarboximidamide; - N-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxyphenylJ-N’{{4-[2-thienyl(iminomethyl)aminoJphenyl}carbonylamino}-urea; - (R)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonylj-1 -piperazinyljphenyl} -2-thiophenecarboximidamide; - (S)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbony 1J-1 -piperazinyljphenyl} -2-thiophenecarboximidamide; or a salt of one of the latter, in particular a hydrochloride, dihydrochloride, fumarate or hemi-fumarate of one of the latter.

6. Product according to claim 1 or 2, characterized in that it is one of the following compounds: - 4-acetoxy-3,5-dimethoxy-N- {4-[2-[2-thienyl-(iminomethyl)aminojpheny 1J ethyl} -benzamide; - 3,5-dimethoxy-4-hydroxy-N- {4-[2-[2-thienyl-(iminomethyl)aminojphenyljethyl}-benzamide; or a salt of the latter, in particular a hydrochloride, dihydrochloride, fumarate or hemi-fumarate of one of the latter. «7. Product according to claim 1 or 2, characterized in that it is the N- {4-[4-[3,5-bis-( 1,1 -dimethylethyl)-4-hydroxybenzylJ-1 -piperazinyljphenyl} 2-thiophenecarboximidamide; or a salt of the latter, in particular the hydrochloride, dihydrochloride, fumarate or hemi-fumarate of the latter.

8. Product according to claim 1 or 2, characterized in that it is one of the following compounds: - N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonylj-l-piperazinyljphenyl}-2-thiophenecarboximidamide; - (R)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonylj-1 -piperazinyljphenyl} -2-thiophenecarboximidamide; - 79 - (S)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbony 1J-1 -piperazinyljphenyl} -2-thiophenecarboximidamide; or a salt of one of the latter, in particular a hydrochloride, dihydrochloride, fumarate or hemi-fiimarate of one of the latter.

59. Product according to claim 8, characterized in that it is (S)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran2-yl)-carbonyl]-l-piperazinyl]phenyl}-2-thiophenecarboximidamide, or a salt of the latter, in particular a hydrochloride, dihydrochloride, fumarate or hemi-fumarate of the latter.10 10. As a new industrial product, product characterized in that it corresponds to the general formula (II)A: in which: W represents an amino or nitro radical, A represents: either a radical in which Ri and R2 represent, independently, a hydrogen atom, a halogen, the OH group, a linear or branched alkyl or alkoxy radical with 1 to 6 carbon atoms, R3 represents a hydrogen atom, a linear or branched alkyl radical with 1 to 6 carbon atoms or a -COR4 radical, 25 R4 representing a linear or branched alkyl radical with 1 to 6 carbon atoms, or a radical in which R3 has the meaning indicated above or a H radical in which Rg represents a hydrogen atom, the OH group or a linear or branched alkyl or alkoxy radical with 1 to 6 carbon atoms; X represents -Zj-, -Z|-CO-, -CH=CH-CO-, -Z[-NR3-CO-, -Zi-NR3-CS-, -Z[-NR3-SO2- or a single bond; Y represents a radical chosen from the -Z2-Q, piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, 4-aminopiperidine, -NR3-Z2-Q-, -NR3-CO-Z2-Q-, -NR3-NH-CO-Z2-, -nh-nh-z2-, -nr3-o-z2-, -NR3-SO2-NR3-Z2-, -O-Z2-Q-, -O-CO-Z2-Q- or -S-Z2-Q- radicals, in which Q represents a single bond, O-Z3, R3-N-Z3 or S-Z3; ♦ Zi, Z2 and Z3 represent independently a single bond or a linear or branched alkylene radical with 1 to 6 carbon atoms, Zj, Z2 and Z3 preferably representing -(CH2)m-, m being an integer from 0 and 6; Rg represents a hydrogen atom or an OH group; with the exception however of 3,5-bis-(l,l-dimethylethyl)-4-hydroxy-N-(4nitrophenyl)-benzamide; or a salt of a product of general formula (II)A, with the exception however of the compounds corresponding to the following formulae: -81H Η N. N. NH2 and och3 och311. As a new industrial product according to claim 10, product characterized in that it is one of the following compounds: 1' {[3,4-dihydro-6-methoxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2yl]carbonyl}-4-(4-nitrophenyl)piperazine; l-{[3,4-dihydro-6-methoxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2yl]carbonyl}-4-(4-aminophenyl)piperazine; - hexahydro-4-(4-nitrophenyl)-lH-l,4-diazepine; 1- [(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran-2-yl)carbonyl] hexahydro-4-(4-nitropheny 1)-1 Η-1,4-diazepine; 1 -(4-aminophenyl)-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1 benzopyran-2-yl)carbonyl] hexahydro-lH-l,4-diazepine; N-[4-{4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l- benzopyran-2yl)carbonyl]-1 Η-1,4-diazepin-1 -yl} phenyl]-2-thiophenecarboximidaraide hydrochloride; ( / ?)-3,4-dihydro-2,5,7,8-tetramethyl-2-{4-[(4-nitrophenyl)-l-piperazinyl]carbonyl} -2H-1 -benzopyran-6-ol; - (7?)-3,4-dihydro-2,5,7,8-tetramethy 1-2- {4-[(4-aminophenyl)-1 -piperazinyl]carbonyl}-2H-l-benzopyran-6-ol; (5)-3,4-dihydro-2,5,7,8-tetramethy 1-2- {4-[(4-nitrophenyl)-1 -piperazinyl]carbonyl} -2H-1 -benzopyran-6-ol; (5)-3,4-dihydro-2,5,7,8-tetramethyl-2- {4-[(4-aminophenyl)-l -piperazinyl]carbonyl} -2H-1 -benzopyran-6-ol; 3.5- bis-(l,l-dimethylethyl)-4-hydroxy-N-[2-(3-nitrophenyl)ethyl]-benzamide; 3.5- bis-(I,I-dimethylethyl)-4-hydroxy-N-[2-(3-aminophenyl)ethyl]-benzamide; 2- (4-nitrophenyl)ethyl 3,5-bis-(l, 1-dimethylethyl)-4-hydroxybenzoate; 2-(4-aminopheny 1 )ethy 13,5-b is-( 1,1 -dimethylethy l)-4-hydroxy-benzoate; or a salt of one of the latter. -8212. Process for the preparation of a product according to any one of claims I to 9, characterized in that a compound of general formula (III) A—X— (III) is reacted, in a lower alcohol such as methanol, ethanol, isopropyl alcohol or tbutanol, preferably in isopropyl alcohol, with a compound of general formula (IV), B H (IV) said compound of general formula (IV) being optionally able to be salified by a mineral acid G, preferably HC1, HBr or HI, the compounds of general formulae (III) and (IV) being such that: A represents: either a radical, Ri and R2 representing, independently, a hydrogen atom, a halogen, the OH group, a linear or branched alkyl radical with 1 to 6 carbon atoms, a linear or branched alkoxy radical with 1 to 6 carbon atoms, Rj representing a hydrogen atom, a linear or branched alkyl radical with 1 to 6 carbon atoms or a -COR4 radical, and R4 representing a linear or branched alkyl radical with 1 to 6 carbon atoms, -83or a CH3 r3o, h3c ch3 ch3 radical in which R3 has the meaning indicated above or a H radical in which R5 represents a hydrogen atom, the OH group or a linear or branched alkyl or alkoxy radical with 1 to 6 carbon atoms; B represents a linear or branched alkyl radical with 1 to 6 carbon atoms, carbocyclic or heterocyclic aryl radical with 5 or 6 members containing 1 to 4 heteroatoms chosen from O, S, N and more particularly: thiophene, furane, pyrrole or thiazole, the carbons of which are optionally substituted by one or more groups chosen from an alkyl, an alkenyl or an alkoxy radical with 1 to 6 carbon atoms and being linear or branched; L represents a leaving group, and in particular a thioalkyl radical, sulphonic acid, trifluoromethanesulphonic acid, halide, aryl alcohol or tosyl; X represents -Zr, -Zi-CO-, -CH=CH-CO-, -Z]-NR3-CO-, -ZrNR3-CS-, -Zi-NR3-SO2- or a bond; Y represents -Z2-Q, piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, 4-aminopiperidine, -NR3-Z2-Q-, -NR3-CO-Z2-Q-, -NR3-NH-CO-Z2-, -NH-NH-Z2-, -NR3-O-Z2-, -NR3-SO2-NR3-Z2-, -O-Z2-Q-, -O-CO-Z2-Q- or -S-Z2-Q-, with bond, O-Z3, R3-N-Z3 or S-Z3; Zi, Z2 and Z3 represent independently a bond or a linear or branched alkylene radical with 1 to 6 carbon atoms; Rg represents a hydrogen atom or an OH group. -8413. As a medicament, a product of general formula (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt of this product.

14. Pharmaceutical composition containing as active ingredient at least one product according to claim 13. 5 15. Pharmaceutical composition containing as active ingredient (S)-N-{4-[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l-benzopyran2-y l)-carbony 1]-1 -piperazinyljphenyl} -2-thiophenecarboximidamide or a pharmaceutically acceptable salt of the latter.

16. Use of a product of general formula (I) according to any one of claims 1 to 9, or 10 of a pharmaceutically acceptable salt of this product, for producing a medicament intended to inhibit neuronal NO synthase.

17. Use of a product of general formula (I) according to any one of claims 1 to 9, or of a pharmaceutically acceptable salt of this product, for producing a medicament intended to inhibit inducible NO synthase.15 18. Use of a product of general formula (I) according to any one of claims 1 to 9, or of a pharmaceutically acceptable salt of this product, for producing a medicament intended to inhibit lipidic peroxidation.

19. Use of a product of general formula (I) according to any one of claims 1 to 9, or of a pharmaceutically acceptable salt of this product, for producing a medicament20 having both an inhibition activity on NO synthase and on lipidic peroxidation.